Supporting Information for 1

The effect of combining antibiotics on resistance: A systematic 2

review and meta-analysis 3

- Berit Siedentop^{1,2*}, Viacheslav N. Kachalov^{2,3}, Christopher Witzany¹, Matthias Egger^{4,5,6}, Roger D.
- Kouyos^{2,3†}, Sebastian Bonhoeffer^{1*†}
- 4 5 6 7 8 ¹ Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland
- ² Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University 9

1

- 10 of Zürich, Zürich, Switzerland
- 11 ³ Institute of Medical Virology, University of Zurich, Zurich, Switzerland
- 12 ⁴ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
- 13 ⁵ Population Health Sciences, University of Bristol, Bristol, UK
- 14 ⁶ Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences,
- 15 University of Cape Town, Cape Town, South Africa
- 16 [†]These authors contributed equally
- 17 *Berit Siedentop, Sebastian Bonhoeffer
- 18
- 19
- 20 21

22

23

24

28 Supporting Information Text

29 **1.** Definitions of resistance development

30 To measure resistance development in patients with standard clinical routines is 31 challenging. Without antibiotic pressure a resistant strain might be present within the patient at 32 low frequency and might not be detected with a culture due to detection limits. With antibiotic 33 treatment the frequency of this resistant strain might rise and therefore the strain might be 34 detected in a follow-up culture. In this case resistance did not develop de novo, but it is difficult to 35 distinguish this case from an event where it did. Furthermore, the genetic relatedness is not 36 always checked between initial and follow-up cultures, meaning that the resistant bacterium at a 37 follow-up culture could have been also transmitted from a different body cite or from other 38 infection sources. To give a more comprehensive overview of how antibiotic treatment strategies 39 might affect the resistance development, we therefore choose to present the results of two 40 resistance estimates. A broader estimate, acquisition of resistance, and a stricter estimate de 41 novo emergence of resistance, where the latter is a subset of the former. A patient is considered 42 to have acquired resistance, if at the follow-up culture there has been a resistant (as defined by 43 the study authors) bacterial species detected, that has not been detected in the baseline culture. 44 A patient is considered to have *de novo* emergence of resistance, if at follow-up up culture a 45 resistant bacterium was detected, that has already been detected at the baseline culture, but 46 sensitive. De novo emergence of resistance is nested in the definition of acquisition of resistance. 47 In acquisition of resistance we account for bacteria at low abundance that could have been 48 already present at the beginning of treatment, but not detected at screening. In this definition it is 49 impossible to distinguish though, whether the bacteria already colonised the patient or whether 50 the patient was newly infected by an external source during treatment and when the bacterium 51 developed resistance. We also included the stricter definition *de novo* emergence of resistance. 52 For de novo emergence we only consider cases where a sensitive bacterium was cultured at 53 baseline. In this definition it is less likely to count cases, where resistant bacteria were transmitted 54 from an external source, as a de novo emergence event. But there are cases, which are counted 55 as an event of *de novo* emergence of resistance, where in fact resistance did not develop newly, 56 but resistance was only selected during treatment. This could be the case when a sensitive 57 bacterium was cultured at baseline and the same kind of bacterium was also present at a non-58 detectable frequency as a resistant phenotype. Overall both resistance development definitions 59 have their limitations and capture slightly different impacts of antibiotic treatment on resistance.

In the main manuscript we showed results for the outcome acquisition of resistance and in
 the following section the main pooled estimates for *de novo* emergence of resistance are
 presented.

63 2. Main estimates for *de novo* emergence of resistance

As for acquisition of resistance (main text figure 3), we did not identify a difference of using a higher number of antibiotics in comparison to less if *de novo* emergence of resistance is considered.

67 Counterintuitively, for *Mycobacterium tuberculosis* (Mtb) – which may be regarded as the flagship 68 of antibiotic combination therapy – we could only identify two studies matching our inclusion

69 criteria via our systematic search (main text figure 3, figure S1). Since the 1950s the

administration of antibiotics often changes within the Mtb treatment period (1, 2). With the early

rol administration of antibiotics often changes within the Mb treatment period (1, 2). With the early rol establishment of changing antibiotics within the Mtb treatment period, it would be understandable,

that resistance development measurements of periods with fixed antibiotic treatment, which is an

73 inclusion criterion for our review, got less frequent over the years. Therefore, the relatively small

74 proportion of Mtb studies included in our review is not surprising.

Α		Γ	Number of antit	biotics compared	В	Antibi	otics	Number of 1 vs. 2	antibiotics compared 2 vs. 3 3 vs. 4
Study / subgroup	Antibi Less (n/N)	otics More (n/N)	OR (95% CI)	OR (95% CI)	Study / subgroup	Less (n/N)	More (n/N)	OR (95% CI)	OR (95% CI)
MRSA									
Parras 1995 ³³	0/37	0 / 36			MAC				
Harbarth 2015 ¹⁹	0/69	0/68		0.15 (0.00 to .10.40)	Fournier 1999 ¹⁵	0/16	0/18		
Walsh 1993	3/45 0/117	9/49		2.62 (0.11 to 64.95)	Dubé 1997 ¹³	16/35	11 / 45		0.38 (0.15 to 0.99)
Pujol 2021 ³⁸	1/81	0 / 74		0.36 (0.01 to 8.98)	Chaisson 1997 ⁸	1/48	0/41		0.38 (0.02 to 9.62)
RE Model for Subgroup ($I^2 = 1$)	$2\%, \tau^2 = 0.0$	02)	-	2.53 (0.73 to 8.80)	May 1997 ²⁵	21/67	2/67		0.07 (0.02 to 0.30)
MAC					RE Model for Subgroup (I ²	$= 26.8\%, \tau^2 = 0$	H24)	•	0.18 (0.06 to 0.52)
Fournier 1999 ¹⁵	0/16	0/18		0.22 (0.15 to 0.00)	H pylori				
Chaisson 1997 ⁸	1/48	0/41		0.38 (0.02 to 9.62)	Hultón 1007 ²²	4/53	3/52	_	0.75 (0.16 to 2.52)
May 1997 ²⁹	21 / 67	2 / 67	—	0.07 (0.02 to 0.30)	Steels 1009 ⁴³	3/18	0/35		0.06 (0.00 to 1.28)
RE Model for Subgroup (I ² = 20	$6.8\%, \tau^2 = 0$	·24)	•	0.18 (0.06 to 0.52)	Slack 1996 Wurzer 1997 ⁴⁷	26 / 104	2/102		0.06 (0.01 to 0.26)
H. pylori									,
Miehlke 1998 ³²	0/73	0/78		0.75 (0.16 to - 9.59)	RE Model for Subgroup (I ²	$= 41.7\%, \tau^2 = 0$	ŀ64)	•	0.14 (0.03 to 0.55)
Stack 199843	3/18	0/35		0.06 (0.00 to 1.28)	P. aeruginosa				
Wurzer 199747	26 / 104	2 / 102	<u>→</u>	0.06 (0.01 to 0.26)	Mc Carty 1988 ³⁰	0/8	0/9		
RE Model for Subgroup (I ² = 4	$1.7\%, \tau^2 = 0$	·64)	-	0.14 (0.03 to 0.55)	Smith 199942	2/30	11/40		5.31 (1.08 to 26.13)
P. aeruginosa									
Mc Carty 1988 ³⁰	0/8	0/9			MRSA				
Smith 1999 ⁴² Hodson 1987 ²⁰	2/30	11/40 3/20		5.31 (1.08 to 26.13) 1.59 (0.24 to 10.70)	Walsh 199344	3 / 45	9 / 49	-	3.15 (0.80 to 12.48)
BE Model for Subgroup (I ² – 1)	$-5\% \tau^2 = 0.0$	11)		3:42 (1:03 to 11:34)	Pujol 2021 ³⁸	1/81	0 / 74		0.36 (0.01 to 8.98)
	576, 1 = 01	,		342 (10310 1134)	RE Model for Subgroup (I ²	$= 0.8\%, \tau^2 = 0.0$	D1)	-	2.28 (0.64 to 8.10)
Gibson 1989 ¹⁷	0/52	0 / 50							
Jacobs 1993 ²⁴	2/13	2/14		0.92 (0.11 to 7.67)	M.tuberculosis				
M.tuberculosis					Macnab 1994 ²⁰	0/1/3	0/146		
Macnab 1994 ²⁶	0/173	0 / 146	i		Dawson 2015	0/118	0/59		
Dawson 2015	07118	0759			Resistant A. baumannii				
UII Iravani 1981 ²³	0/65	0 / 58			Durante-Mangoni 201314	0 / 105	0 / 104		
Skin microbiota of healthy v	olunteers				Brophylaxic for homotoly	aioal maliana	nov pationto		
Jo 2021 ²⁵	6/8	3/3	-	2.69 (0.10 to 73.20)	Prophylaxis for memaloid	0 / 20	1 / 18		0.51 (0.12 to 01.07)
Serious bacterial infection					Bender 1979	0720	17 10		3.51 (0.13 (0.91.87)
Hoepelman 1988 ²¹	0 / 48	9 / 44		-25.96 (1.46 to 460.84)	Pneumonia, sepsis, peri	tonitis			
S. aureus					Cometta 19949	6/8	9 / 13		0.75 (0.10 to 5.47)
Markowitz 1992 ²⁷	0 / 58	0 / 43			Neutropenia				
Resistant A. baumannii	0 / 105	0/104			Jacobs 1993 ²⁴	2/13	2/14	_	0.92 (0.11 to 7.67)
Durante-Mangoni 2013		07104							0.02 (0.11 (0.7 01)
Prophylaxis for hematologic Bender 1979 ⁶	al malignar 0 / 20	1 / 18	nts	3-51 (0-13 to 91-87)	Multidrug resistant typhi	od fever			
Pneumonia sensis neritoni	tie				Parry 2007 ³⁵	0 / 125	0 / 67		
Cometta 1994 ⁹	6/8	9 / 13		0.75 (0.10 to 5.47)	Gram–negative resistant	BSI, pneumor	ia		
Multidrug resistant typhiod f	ever				Pogue 2021 ³⁷	23 / 191	16 / 189	-+-	0.68 (0.34 to 1.32)
Parry 200735	0 / 125	0 / 67							
Gram–negative resistant BS	l, pneumon	ia			E. coli				
Pogue 2021 ³⁷	23 / 191	16 / 18	9 🔸	0.68 (0.34 to 1.32)	Black 1982'	5/10	0/10		0.05 (0.00 to 1.03)
Gram-negative hopsital acq	uired infect	tion	<u>_</u>		Carbapenem resistant in	fections			
Rubinstein 1995	12/201	14723		1.34 (0.61 to 2.97)	Dickstein 202012	6 / 106	7 / 108	-	1.16 (0.38 to 3.56)
E. COII Black 1982 ⁷	5/10	0/10		0.05 (0.00 to 1.03)	Total (95% CI)	119 / 137	74 73 / 1260	•	0·45 (0·20 to 1·02)
Cholangitis					Heterogeneity: τ ² =1·56; I ² =	-73%			
Gerecht 1989 ¹⁶	0/24	0 / 22				Favors a hi	gher number of	antibiotics Favors few	er antibiotics
Carpenem resistant infection	ıs						Г		I
Dickstein 2020 ¹²	6 / 106	7 / 108	· +	1.16 (0.38 to 3.56)			0	0.04 1 25.79	
Total (95% CI) Heterogeneity: 7 ² -1.94: 1 ² -77%	139 / 220	06 103 / 2	047 🔶	0.74 (0.34 to 1.59)					
	Equero o bi	abor numt-	ar of antibiotica - Four-	wer antibiotics					
	ravors a nij	gnar numbe							

0 0.04 1 25.79

Fig. S1. Forest plot of *de novo* emergence of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were

compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of

studies with at least one antibiotic in common in the treatment arms. MRSA stands for methicillin-

81 82 resistant Staphylococcus aureus, MAC for Mycobacterium avium complex, and BSI for blood stream infection.

- 83

84 2.1. All studies

85 For all studies meeting our inclusion criteria and reporting data of *de novo* emergence of 86 resistance our estimate did not suggest a difference between using a higher number of antibiotics 87 in comparison to less. This result was in line with our main outcome acquisition of resistance. 88 Nevertheless, for *de novo* emergence of resistance there was a slight trend observable which 89 suggested a benefit of using a higher number of antibiotics. However, we could not identify a 90 clear benefit (pooled OR 0.74, 95% CI 0.34 - 1.59, figure S1 A). This trend might be due to the 91 stricter definition of de novo emergence relative to acquisition of resistance. In the definition of 92 acquisition of resistance bacterial species that are different from the initial identified infecting 93 organism are included, whereas for *de novo* emergence of resistance they are not necessarily 94 included. For de novo emergence of resistance, the efficacy of antibiotic treatment against the 95 considered bacteria is therefore expected to be higher as for acquisition of resistance, as 96 antibiotics typically have a specific bacterial spectrum of activity. The model including all studies 97 reporting *de novo* emergence of resistance showed a substantial amount of heterogeneity 98 (*I*²=77%, figure S1A). 99

2.2. Studies with at least one antibiotic common to both treatment arms

100 To compare more similar antibiotic treatments, we also estimated the effect of *de novo* 101 emergence of resistance based on studies, that had at least one antibiotic common to the 102 comparator arms. With this restriction we also did not identify a difference of using a higher 103 number of antibiotics in comparison to less, but we observed a stronger tendency of a benefit of 104 using a higher number of antibiotics (pooled OR 0.45, 95% Cl 0.20 – 1.02, figure S1B). The 105 model for studies reporting *de novo* emergence of resistance, and with at least one common 106 antibiotic in the comparator arms showed still a substantial amount of heterogeneity ($I^2=73\%$, 107 figure S1B).

108 3. Risk of bias assessment

109 To assess the risk of bias for our two main outcomes we used the RoB 2 tool (3). The results of 110 the risk of bias assessments for acquisition, and *de novo* emergence of resistance differed only 111 marginally, which can be explained by the overlap of those two definitions. We defined de novo 112 emergence of resistance as a stricter subset of acquisition of resistance (section 1). In both cases 113 two studies were classified overall with a low risk of bias, and about 50 % percent of the studies 114 were classified overall with some concerns of bias (67% acquisition of resistance, 72 % 115 emergence of resistance, figure S2). The highest source of at least some concern was the 116 selection of the reported results. As development of resistance is not a typical main objective of 117 RCTs, and since we included a large proportion of rather old studies, the resistance outcome is 118 often not well (pre-)defined (table S1) and not presented in a systematic way, which can explain 119 the risk of bias observed in the category "selection of the reported results". Since the studies were 120 rather underpowered (main text: figure 2B) to detect the resistance development, missing data 121 was commonly a high risk of concern in the domain "deviations from intended interventions". The 122 detailed output of the risk of bias assessment using the RoB 2 tool can be found at OSF under 123 the following link "https://osf.io/gwefv/?view_only=f6a4c1f4c79241038b203bd03c8e1845".



Fig. S2. Risk of bias summary for the two main outcomes: A) Acquisition of resistance, B) *denovo* emergence of resistance.

128

Table S1. Justification for extraction of resistance development. The definitions of resistance development are stated as given by study authors. In case no explicit definition was given, we state a justification for extraction and indicate it with (*). Note that for data extraction for the

131 state a justification for extraction and indicate it with (*). Note that for data extraction for the 132 publications of Dekker et al. 2015 and Pogue et al. 2021 additional publications of the same

133 studies were consulted (Paul et al. 2018 (4) and Kaye et al. 2022 (5) respectively). Resistance

breakpoints are stated in case numerical values were given in the respective studies. See table 1

in the main text for which antibiotics the studies tested and reported extractable resistance data.

Study	Definition of resistance development given by study authors or justification for extraction
Bender et al. (1979) (6)	Susceptibility testing for gentamicin of the flora was performed at randomisation and twice weekly after with Kirby-Bauer disk technique and microtiter minimal inhibitory concentration. (*)
Black et al. (1982) (7)	Patients were infected with a known strain and all stool cultures and rectal swabs were plated and tested for trimethoprim resistance. (*)
Chaisson et al. (1997) (8)	Testing of isolates for susceptibility for clarithromycin, ethambutol, and clofazimine was performed before the entry of study and monthly for 6 months in broth by the method of Heifets.(*)
Cometta et al. (1994) (9)	All microorganisms were sensitive to imipenem at randomisation and follow-up cultures were performed. (*) $% \left(\left({{\left({{\left({{\left({{\left({{\left({{\left({{$
Dawson et al. (2015) (10)	Susceptibility testing at randomisation and for the following cultures by rapid testing. Susceptibilities to isoniazid, rifampicin, and fluoroquinolones were determined by line probe assay. (*)
Dekker et al. (1987) (11)	At admission cultures were performed and surveillance culture were done twice a week. Gram negative bacilli were tested for antibiotic susceptibility. The minimal inhibitory concentrations were assessed by agar dilution technique. An MIC of $\ge 2 \ \mu g/mL$ was considered resistant for ciprofloxacin, an MIC of $\ge 4 \ \mu g/mL$ for trimethoprim and an MIC $\ge 75 \ \mu g/mL$ for sulfamethoxazole. (*)
Dickstein et al. (2019) (12)	Development of a new colistin-resistant (CoIR) isolate within 28 days from study enrolment. To be considered a new CoIR isolate, the CoIR isolate had to be detected on Day seven or later in patients for whom the baseline isolate was colistin-susceptible, and for whom no CoIR isolate was cultured from the rectal swab taken on Day one. Susceptibility was determined by broth microdilution. Colistin resistance was defined as an MIC > 2mg/L.

Dubé et al. (1997) (13)	All available isolates were tested for susceptibility to clarithromycin. Patients were evaluated at the time of enrolment, two and four weeks later, and then every four weeks. Clarithromycin resistance was defined as detectable growth in a concentration of clarithromycin of 8 µg/mL. (*)
Durante-Mangoni et al. (2013) (14)	The identification of a colistin resistant <i>Acinetobacter baumannii</i> during treatment was defined as resistance emergence. Resistance was determined by microdilution method and/or E-test.
Fournier et al. (1999) (15)	Susceptibility testing was performed at study entry and after 2 months and classification was performed according to Heifets. (*)
Gerecht et al. (1989) (16)	Emergence of resistance was defined as one cause of treatment failure. Emergence of resistance was classified as the detection of an infecting microorganism resistant to more than 4 µg/mL of gentamicin sulfate or more than 128 µg/mL of mezlocillin sodium during treatment while the patient shows indications of cholangitis.
Gibson et al. (1989) (17)	Microbiological assessment of the blood was performed before treatment and 96 hours after treatment. (*)
Haase et al. (1984) (18)	Susceptibility was assessed before therapy, during therapy and after therapy. Susceptibility testing was performed with disk dilution method, and agar dilution method. Resistance results were reported for reinfections defined as the reappearance of infection with a different organism after completion of therapy. Resistance against norfloxacin and trimethoprim-sulfamethoxazole was defined as a larger inhibition zone diameter of 0.17 and 0.16 mm, respectively, or/and a MIC larger than 16 μ g/mL and 3.4-64 μ g/mL, respectively. (*)
Hartbarth et al. (2015) (19)	Susceptibility assessment was performed at baseline and at the end of treatment. Susceptibility was performed with a disc diffusion method phenotypically and genotypically. (*)
Hodson (1987) (20)	<i>P. aeruginosa</i> had to be sensitive at inclusion and resistance was measured and reported after 10 days of treatment. Sensitivity was determined by standard disc methods. (*)
Hoepelman et al. (1988) (21)	Susceptibility was assessed before, during, and after treatment. Susceptibility testing was performed with disc diffusion method and minimum inhibitor concentrations were assessed for blood cultures and patients with no response to treatment with agar dilution technique. Resistance for the agar dilution technique was defined as an MIC of \geq 32 µg/mL for ceftriaxone, \geq 8 µg/mL for gentamicin and \geq 32 µg/mL for cefuroxime. For the disc diffusion method 30 µg ceftriaxone, 40 µg gentamicin and 60 µg cefuroxime were used. If the zone of inhibition was <18 mm cultures were classified as ceftriaxone resistant and sensitive if the zone was ≥26 mm and intermediate in between. For gentamicin the values were <20mm and ≥28mm and for cefuroxime <20mm and ≥28mm, respectively.(*)
Hultén et al. (1997) (22)	Susceptibility was assessed by E-test at inclusion and 12 weeks after treatment determination. (*)
Iravani et al. (1981) (23)	Susceptibility testing at baseline, during treatment and at follow-up. Testing was performed with Bauer's disc diffusion method using 30 μ g nalidixic acid, 1.25 μ g trimethoprim and 23.75 μ g sulfamethoxazole. (*)
Jacobs et al. (1993) (24)	Emergence of resistance was defined as treatment failure with resistance, i.e., bacteriological failure with the reisolation of original pathogen(s) resistant to the study antibiotic(s) after treatment.
Jo et al. (2021) (25) Macnab et al.	Susceptibility testing before treatment and after treatment by culture. (*) Susceptibility testing before treatment and after around 90 doses. (*)
(1994) (26) Markowitz et al. (1992) (27)	Susceptibility was assessed by microdilution method before treatment and for the last continuous positive culture during treatment. Furthermore, susceptibility was assessed for
Mavromanolakis et	relapse isolates and isolates phenotypically different from the initial one. (*) Susceptibility was assessed before treatment, after 2 weeks, at the end of treatment, and 2
al. (1997) (28) May et al.	weeks after treatment by disk diffusion method. (*) Susceptibility was assessed at treatment start, after two months, and in case of relapse by the
(1997) (29) Mc Carty et al. (1988) (30)	Becton Dickinson method. (*) Susceptibility was assessed at admission, every four days during treatment, and within 48 hours after treatment by broth microdilution method using the American Microscan Gram Negative- Panel. (*)
Menon et al. (1986) (31)	Susceptibility was assessed before therapy, and after one and two weeks after therapy. (*)
Miehlke et al. (1998) (32)	Susceptibility was assessed before and after treatment by E-test. An MIC of ≤ 0.125 mg/L was considered clarithromycin sensitive and an MIC of ≥ 2 mg/L resistant. An MIC of ≤ 2 mg/L was considered amoxicillin susceptible and an MIC of ≥ 4 mg/L resistant. (*)
Parras et al. (1995) (33)	Susceptibility was assessed at baseline and at end of therapy by agar dilution method or automated microdilution methods. (*)
Parry et al. (1977) (34)	Susceptibility was assessed before, during, after treatment, after two weeks, and after six months after treatment by Bauer's method. (*)
Parry et al. (2007) (35)	Susceptibility was assessed before therapy and after treatment by E-test, disk diffusion method. Ofloxacin was tested by disk diffusion method with a 5 μ g and organisms were declared susceptible with a breakpoint $\leq 2 \mu$ g/mL and resistant with a breakpoint $\geq 8 \mu$ g/mL. Azithromycin

	was also tested with disk diffusion method (15 µg disk), but no clear breakpoint were defined. Instead azithromycin was determined by E-test according to the manufacture's guideline. (*)
Paul et al. (2015) (36)	Development of resistance was defined as acquisition of <i>S. aureus</i> resistant to any of the study drugs or vancomycin resistant <i>Enterococci</i> .
Pogue et al. (2021) (37)	Number of patients, who developed colistin resistance during therapy. Resistance was assessed with broth microdilution and declared as colistin resistant with an MIC \geq 4 mg/L.
Pujol et al. (2021) (38)	Emergence of resistance to study drugs during treatment according to EUCAST.
Rubinstein et al. (1995) (39)	Resistance emergence was assessed by measuring MICs before, during and after treatment. Disk diffusion testing was performed with disks of 30 μ g ceftazidime, 30 μ g ceftriaxone and 10 μ g tobramycin. An MIC ≤8 mg/L was considered susceptible for ceftazidime and ceftriaxone and a MIC ≥ 32 mg/L was considered resistant for ceftazidime and an MIC ≥ 64 mg/L for ceftriaxone. An MIC ≤4 mg/L was classified as susceptible for tobramycin, and an MIC ≥ 8 mg/L as resistant.
Schaeffer et al. (1981) (40)	Susceptibility was assessed before therapy, after 7 days, and after five to nine days after therapy by plating. Susceptibility testing was performed by plating 0.1mL of culture on Mac Conkey agar containing 100 μ g/mL cinoxacin or 1-24 μ g/mL trimethoprim-sulfamethoxazole. Any growing culture was considered resistant and resistance tests were confirmed with standard agar sensitivity testing to a maximum concentration of 100 μ g cinoxacin or 80-400 μ g trimethoprim-sulfamethoxazole. (*)
Schaeffer et al. (1985) (41)	Susceptibility testing was performed before therapy, during therapy, and after five to seven days after therapy by plating. 0.1 mL of cultures were plated on either Mueller-Hinton agar containing 10 μ g/mL agar of norfloxacin or 1-24 μ g/mL agar trimethoprim-sulfamethoxazole with 5 % lysed red blood cells from the horse. Any growing culture was considered resistant and resistance tests were confirmed with tube dilution sensitivity testing to a maximum concentration of 100 μ g/mL norfloxacin or 32-608 μ g/mL trimethoprim-sulfamethoxazole. (*)
Smith et al. (1999) (42)	Susceptibility was assessed at inclusion, at end of treatment by disk-susceptibility testing. An MIC of \geq 100 µg/mL was considered resistant for azlocillin and resistant to tobramycin if the MIC was \geq 8 µg/mL.(*)
Stack et al. (1998) (43)	Susceptibility was assessed at baseline, and at four or eight weeks after treatment by E-test. Resistance was considered with bacterial growth at a drug concentration of >2 µg/mL for clarithromycin. (*)
Walsh et al. (1993) (44)	Susceptibility was assessed at baseline and for organisms culturable after the end of therapy and a two-week follow-up period by a microtiter tube dilution technique. Organisms were declared resistant if the MIC was greater than 2 μ g/mL for rifampicin, greater than 8 μ g/mL for novobiocin, and greater than 2 μ g/mL and 38 μ g/mL for trimethoprim and sulfamethoxazole.
Winston et al. (1986) (45)	Susceptibility of surveillance cultures was assessed at baseline, twice weekly during the study period and after study completion. Acquired organisms were defined as new organisms isolated during the study period, that were not present at baseline. An MIC \leq 16 µg/mL was considered as sensitive for norfloxacin, polymyxin. For disc sensitivity testing cultures were considered sensitive to norfloxacin if a zone of \geq 17 mm was present in a 10 µg norfloxacin disk. (*)
Winston et al. (1990) (46)	New organisms that were isolated during the study period but have not been present before the study were defined as acquired organisms. Susceptibility tests were done by agar dilution method, or by antibiotic disks. An MIC of \leq 4, 16, or 4 µg/mL for ofloxacin, polymyxin, or vancomycin was considered susceptible to the antibiotics, respectively. For ofloxacin additional disk sensitivity testing was performed. Susceptibility was declared if a zone of 16mm or greater was present around a 5- µg disk of ofloxacin. (*)
Wurzer et al. (1997) (47)	Susceptibility was assessed pre-treatment and between 4 and 6 weeks of follow-up by agar dilution, and microbroth dilution. An MIC concentration of $\leq 2 \mu$ g/mL indicated susceptibility for clarithromycin, and an MIC above 2 μ g/mL resistance. A MIC lower or equal to 0.125 μ g/mL for amoxycillin was considered susceptible and classified resistant if above 0.125 μ g/mL. (*)

137 **4.** Sensitivity analysis for main estimates

To test the robustness of our main analyses, we performed sensitivity analyses based on the model choice and the risk of bias.

140 **4.1.** Model choice

For our analyses we applied the random effects model 4 described in Jackson et al (48) using the R package *metafor (49)*. To test the robustness of our estimates to the model choice we reran the

main analyses with the conventional random effects model (model 1 in Jackson et al (48)) and an

144 corresponding Bayesian version of model 4 in Jackson et al (48). For the sensitivity analyses the

145 R packages *metafor* (49), and MetaStan(50) with default settings were used. We observe that our

estimates are typically robust to model choice (figures S3, S4). Only for *P. aeruginousa* our

- 147 estimate was not robust in our sensitivity anlaysis, where the alternative two approaches showed
- 148 no harm or benefit of using a higher number of antibiotics (figure S3).
- 149





Fig. S3. Sensitivity analysis based on model choice for the two main outcomes: A) acquisition of resistance, B) *de novo* emergence of resistance. Shown are the frequentist model estimates of model 1, and model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4. UTI stands for urinary tract infection, MRSA for methicillin-resistant *Staphylococcus aureus*, and MAC for *Mycobacterium avium* complex.



Fig. S4. Sensitivity analysis based on model choice for the two main outcomes restricted to
studies with at least one common antibiotic in the comparator arms: A) acquisition of resistance,
B) *de novo* emergence of resistance. Shown are the frequentist model estimates of model 1, and
model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4.

162

163 **4.2.** Impact of risk of bias

164 To assess the impact of risk of bias on our estimates, we reran the main analyses stratifying 165 according to the overall risk of bias. For studies classified with an overall high risk of bias our

166 analysis shows that for acquisition of resistance using a lower number of antibiotics shows a

- benefit (pooled OR 4.45, 95% CI 1.67 11.81; l^2 =57, table S2). We did not observe any
- 168 difference of using a higher number of antibiotics in comparison to less in resistance development 169 when grouping the rest of the studies according to their risk assessment (table S2). Nevertheless.
- 169 when grouping the rest of the studies according to their risk assessment (table S2). Nevertheless, 170 with less risk of bias administering a higher number of antibiotics seemed to perform better in
- 1/0 with less risk of bias administering a higher number of antibiotics seemed to perform better in 171 comparison to less. However, no clear benefit could be determined (table S2). This observation
- additionally supports that RCTs with resistance development as a main objective, and therefore
- 173 potentially decreasing the risk of bias, are needed to understand the impact of different treatment 174 strategies on antibiotic resistance outcomes.
- 175

176 **Table S2.** Summary of the results of the sub-group analyses stratifying according to the overall

177 risk of bias for the two main outcomes. Note that the listing of eligible studies also includes

178 studies reporting zero cases in both treatment arms and were therefore not included in the statistical analysis.

Overall risk of bias	Outcome	OR (95% CI)	Study heterogeneity (<i>I</i> ² ;τ ²)	Eligible studies
Some concerns	Acquisition of resistance	0.71 (0.38-1.32)	72%; 1.15	(6, 7, 9-13, 15, 16, 19, 20, 22, 23, 25, 27-35, 39, 41, 43, 44, 47)
Some concerns	<i>De novo</i> emergence of resistance	0.49 (0.21-1.14)	73%; 1.53	(6, 7, 9, 10, 12, 13, 15, 16, 19, 20, 22, 23, 25, 27, 29, 30, 32- 34, 39, 43, 44, 47)
High	Acquisition of resistance	4.45 (1.67-11.81)	57%; 1.11	(8, 17, 18, 21, 24, 26, 36, 37, 40, 42, 45, 46)
High	<i>De novo</i> emergence of resistance	2.32 (0.65-8.28)	60%; 1.28	(8, 17, 18, 21, 24, 26, 36, 37, 42)

180

181 5. Publication bias

In the study protocol we stated that we will test for publication bias via visual inspection of the funnel plots and by Egger's test. As Egger's test can have problems with false-positive results for dichotomous outcomes, we used a modified version of the Egger's test, i.e. the Harbord's test (51).

186 Neither the visual inspection of the funnel plots (figure S5), nor Harbord's tests gave an indication
 187 for a publication bias for our two main outcomes acquisition, and *de novo* emergence of

resistance (acquisition of resistance: Harbord's: p = 0.28; *de novo* emergence of resistance:
Harbord's: p = 0.51).



192 Fig. S5. Funnel plots for the two main outcomes: A) acquisition of resistance, B) de novo

- 193 emergence of resistance.
- 194

195 6. Sub-group analyses

196 The performance of an antibiotic treatment strategy to minimise resistance spread is not only 197 dependent on the number of antibiotics administered. In our main estimates we found a 198 substantial amount of heterogeneity (main text: figure 3; figure S1), which is an indication that 199 additional factors might be important to consider in a statistical model. In the following we first 200 present the results of in the study protocol pre-defined subgroup analyses and afterwards 201 additional post-hoc subgroup analyses. One must consider that the results are mainly based on 202 underpowered studies (main text: figure 2 B), and that in the subgroup analyses the number of 203 included studies decreases. Therefore, the results of the subgroup analyses should be 204 considered with care.

205 **6.1.** Predefined in study protocol

The results of our subgroup-analyses for the outcome acquisition of resistance and de novo emergence of resistance are summarised in table S3 and table S4 respectively. The rationale for carrying out the predefined sub-group analyses are explained in the following subsections.

209

Table S3. Summary of the results of the predefined sub-group analyses for the outcome acquisition of resistance. Note that the listing of eligible studies also includes studies reporting zero cases in both treatment arms, which are not included in the statistical analysis.

	,		, ,
Sub-group Analysis	OR (95% CI)	Study heterogeneity (<i>I</i> ² ; τ ²)	Eligible studies
Number of antibiotics administered:			

1 vs. 2	1.49 (0.77-2.88)	76%; 1.70	(6, 7, 9, 12, 14, 16-18, 20-25, 27, 28, 30-32, 34-43, 45-47)
2 vs. 3	0.38 (0.08-1.78)	74%; 1.63	(8, 13, 15, 29, 44)
Administration of additional non-antibiotic drugs:			
Non-antibiotic drugs as part of treatment	0.88 (0.21-3.66)	82%; 3.00	(6, 11, 22, 32, 33, 43, 45-47)
Non-antibiotic drugs administered if necessary	1.07 (0.48-2.40)	1%; 0.01	(12, 14, 23, 24, 38)
Usage of same dosage of antibiotics common to both treatment arms	0.59 (0.30-1.18)	73%; 1.20	(6, 8, 9, 12-15, 22, 24, 29, 30, 34, 37, 38, 42- 44, 47)
Required comorbidity at study inclusion:			
Yes	1.23 (0.50-3.01)	72%; 1.59	(6, 8, 11, 13, 15, 17, 20, 24, 27, 29, 30, 34, 42, 45, 46)
No	1.25 (0.55-2.86)	80%; 2.02	(7, 9, 10, 12, 14, 16, 18, 19, 21-23, 25, 26, 28, 31-33, 35-41, 43, 44, 47)
Gram-status			
Negative	1.14 (0.56-2.35)	78%; 1.57	(7, 11, 12, 14, 20, 22, 23, 25, 28, 30-32, 34, 35, 37, 39, 41-43, 45-47)
Positive	0.44 (0.11-1.76)	66%; 1.54	(8, 13, 15, 19, 27, 29, 33, 36, 38, 44)
Negative and positive	3.38 (1.08-10.58)	44%; 0.75	(6, 9, 16-18, 21, 24, 40)
Only resistances of antibiotics common to treatment arms	0.39 (0.18-0.81)	75%; 1.49	(6-10, 12-15, 22, 24, 26, 29-31, 34, 35, 37, 38, 42-44, 47)
Age of antibiotics since conduction of the trial:			
Youngest antibiotic is in the treatment arm with the lower number of antibiotics	1.63 (0.66-4.03)	76%; 2.17	(7, 10, 11, 13, 16-22, 24, 30, 31, 33, 38, 41- 43, 45, 46)
Youngest antibiotic is in the treatment arm with the higher number of antibiotics	1.08 (0.49-2.42)	66%; 0.91	(8, 12, 14, 15, 23, 25, 27-29, 32, 34-37, 39, 40, 44)
No antibiotics common to treatment arms	4.73 (2.14-10.42)	37%; 0.51	(11, 16-21, 23, 25, 27, 28, 32, 33, 36, 39-41, 45, 46)

Table S4. Summary of the results of the predefined sub-group analyses for the outcome *de novo* emergence of resistance. Note that the listing of eligible studies also includes studies reporting zero cases of resistance in both treatment arms, which were therefore not included in the

214 215 216 217

statistical analysis.

Sub-group analysis	OR (95% CI)	Study heterogeneity $(l^2; \tau^2)$	Eligible studies
Number of antibiotics administered:			
1 vs. 2	0.89 (0.38-2.11)	75%; 1.90	(6, 7, 9, 12, 14, 16, 17, 20-25, 27, 30, 32, 34, 36-39, 42, 43, 47)
2 vs. 3	0.38 (0.08-1.78)	74%; 1.63	(8, 13, 15, 29, 44)
Administration of additional non-antibiotic drugs:			
Non-antibiotic drugs as part of treatment	0.22 (0.04-1.10)	82%; 1.10	(6, 22, 32, 33, 43, 47)
Non-antibiotic drugs administered if necessary	0.97 (0.36-2.58)	1%; 0.01	(12, 14, 23, 24, 38)
Usage of same dosage of antibiotics common to both treatment arms	0.53 (0.24-1.16)	71%; 1.38	(6, 8, 9, 12-15, 22, 24, 29, 30, 34, 37, 38, 42- 44, 47)
Required comorbidity at study inclusion:			
Yes	0.71 (0.21-2.41)	67%; 1.57	(6-10, 12-15, 22, 24, 26, 29, 30, 34, 37, 38, 42-44, 47)
No	0.75 (0.28-2.01)	80%; 2.02	(16, 17, 19-21, 23, 25, 27, 32, 33, 36, 39)

Gram status			
Negative	0.60 (0.23-1.55)	78%; 1.59	(7, 12, 14, 20, 22, 23, 25, 30, 32, 34, 37, 39, 42, 43, 47)
Positive	0.44 (0.11-1.76)	66%; 1.54	(8, 13, 15, 19, 27, 29, 33, 36, 38, 44)
Negative and positive	3.34 (0.59-18.97)	47%; 1.39	(6, 9, 16, 17, 21, 24)
Only resistances of antibiotics common to treatment arms	0.32 (0.16-0.66)	59%; 0.87	(6-10, 12-15, 22, 24, 26, 29, 30, 34, 37, 38, 42-44, 47)
Age of antibiotics since conduction of the trial:			
Youngest antibiotic is in the treatment arm with the lower number of antibiotics	0.73 (0.19-2.77)	75%; 2.83	(7, 10, 13, 16, 17, 19-22, 24, 30, 33, 38, 42, 43)
Youngest antibiotic is in the treatment arm with the higher number of antibiotics	0.86 (0.34-2.17)	70%; 0.98	(8, 12, 14, 15, 23, 25, 27, 29, 32, 34, 36, 37, 39, 44)
No antibiotics common to treatment arms	3.54 (0.91-13.75)	38%; 0.68	(16, 17, 19-21, 23, 25, 27, 32, 33, 36, 39)

6.1.1.Number of antibiotics administered

220 In our systematic review we did not predefine a fixed number of antibiotics to compare. We 221 rather aimed to investigate whether there is a general trend of a treatment strategy with a higher 222 number of antibiotics performing better than one with less antibiotics with respect to resistance 223 development. One can imagine though, that the magnitude of this trend might vary depending on 224 the number of antibiotics compared. For example, if resistance against the used antibiotics is 225 likely to be encountered in the population, a comparison of one versus two antibiotics might give 226 different results than two versus three. In the 1960s for Mtb the number of antibiotics was for 227 instance increased to three antibiotics at the initial treatment phase, due to the finding that 228 primary resistance can be encountered for one drug but rarely to two or three antibiotics (2, 52, 229 53). On one hand, if the number of antibiotics used is rather high in both treatment arms, there 230 might be no difference in resistance development detected as the treatment period might be too 231 short to observe a relevant effect. On the other hand, if the treatment period is rather long, there 232 might also not be an efficient effect detectable when a low number of antibiotics is compared and 233 the timespan between follow-up cultures is long. We considered the effect of treatment length, 234 and length of follow-up on our estimates later in the meta-regression and multi-model inference 235 (section 7).

236 We identified three studies comparing one versus three antibiotics, but two of them had zero 237 events for both comparator arms. We included two Mtb studies in our review comparing three 238 versus four antibiotics, but both had zero events in the comparator arms. For the estimates one 239 versus two antibiotics and two versus three antibiotics we did not identify a difference of using a 240 higher number of antibiotics in comparison to less, and substantial heterogeneity was observed 241 (tables S3, S4). Nevertheless, for the estimate two versus three antibiotics there was a beneficial 242 trend for using a higher number of antibiotics observable. However, no clear benefit could be 243 determined (tables S3, S4). This might indicate that in general a higher number of antibiotics in 244 treatments is beneficial. 245

6.1.2. Administration of additional non-antibiotic drugs

246 In our inclusion criteria we allowed the administration of additional non-antibiotic drugs, 247 which potentially could also affect the resistance outcome due to faster cure of patients, or by 248 specifically supporting the activity of antibiotics, as e.g. beta-lactam-inhibitors. To test the effect of 249 the administration of additional non-administered antibiotics, we performed a sub-group analysis 250 based on whether a study administered additional non-antibiotic drugs or not. Notably, in our 251 studies the additional non-antibiotics were always administered in both treatment arms. 252 Considering if additional non-antibiotic drugs were administered or not did not show any harm or 253 benefit on the resistance outcome whether a higher number of antibiotics was used or a lower 254 number (tables S3, S4). A few studies allowed the administration of additional non-antibiotics, but 255 they were not a fixed part of the treatment regime. Also, in those studies we did not identify a 256 harm or benefit (tables S3, S4). 257

6.1.3. Usage of same dosage of antibiotics common to both treatment arms

258 Not only the number of total antibiotics might determine the efficacy of a treatment, but also 259 the dosage of antibiotics. To compare more similar treatments, we estimated the pooled OR for 260 studies that administered at least one antibiotic common to both treatment arms, and where 261 additionally the antibiotics that were common were administered with the same dosage. We 262 observed that in most cases if at least one common antibiotic was administered, their dosage was 263 the same (78% acquisition of resistance, 86% emergence of resistance). Therefore, it is not 264 surprising that we observe, in line with the analysis "at least one antibiotic common to both 265 treatment arms" (main text: figure 3B, figure S1 B), no difference in using a higher number of 266 antibiotics in comparison to less to reduce resistances (tables S3, S4). In both cases we 267 observed a substantial amount of heterogeneity, which indicates that further factors might play a 268 role for explaining the observed resistance differences.

6.1.4. Required comorbidity at study inclusion

270 The way the immune-system reacts to an infection might potentially influence the 271 frequencies of resistances observed (54). Therefore, we tested whether studies that considered 272 patients with a comorbidity, assuming that the immune system is to some extent compromised, 273 show a different trend of resistance development in comparison to studies where no comorbidity 274 was required for study inclusion. For this analysis we considered studies, that had comorbidities 275 as a requirement for study entry. We could not identify a difference of using a higher number of 276 antibiotics in comparison to less for both main outcomes, and regardless of comorbidity status at 277 study entrance (tables S3, S4). 278

6.1.5. Study was conducted in an ICU

279 Another way to test the potential role of the immune system is by severity of illness, 280 approximated whether the study population was treated within an ICU or not. We were not able to 281 link on a patient level the data of resistance development to the patient's ICU status. Therefore. 282 we tried to classify the ICU status per study, i.e. one status for the whole study population. We 283 only identified two studies (5%) for acquisition of resistance, where the whole study population 284 was in the ICU. We found 9 studies (21%), where no patient was treated in the ICU. For the rest 285 of the studies the population could either be mixed (14%), or no information was confidentially 286 extractable (60%). Since the ICU status on a study level seemed to be an uninformative proxy, 287 we decided not to perform sub-group analyses for this factor.

6.1.6.Gram-status

269

288

289 The gram status of a bacterium may potentially determine how effective an antibiotic, or an 290 antibiotic combination is. Differences between gram-negative and gram-positive bacteria such as 291 distinct bacterial surface organisation can lead to specific intrinsic resistances of gram-negative 292 and gram-positive bacteria against antibiotics (55). These structural differences can lead to 293 varying effects of antibiotic combinations between gram-negative and gram-positive bacteria (56). 294 Additionally, plasmids play a major role in the dissemination of antibiotic resistance genes in both 295 gram-positive, and negative bacteria (57). The spread of plasmids differs considerably between 296 gram-positive bacteria and gram-negative bacteria (58). These structural differences could 297 influence the performance of antibiotic treatment strategies. To test the influence of the gram-298 status on our estimates we performed sub-group analyses with studies, that focused only on 299 measurements of gram-negative bacteria, gram-positive, or both. We classified the gram-status 300 on a study level as we could not link the gram-status and resistance development on a patient 301 level.

302 When selecting for studies that either focus on gram-negative, or gram-positive we did not 303 identify a difference in using a higher number of antibiotics in comparison to less for both main 304 outcomes (tables S3, S4). For the subgroup analysis including studies with the focus on both 305 gram-negative and positive bacteria the treatment strategy with a lower number of antibiotics 306 showed a benefit for the main outcome acquisition of resistance (pooled OR 3.38, 95% CI 1.08 – 307 10.58; *I*²=44%, table S3). However, for *de novo* emergence of resistance we did not identify a 308 difference (pooled OR 3.35, 95% CI 0.67 - 16.71; I²=47%, table S4) It seems, that acquisition of 309 resistance is more sensible to the restriction on which gram-status is considered. This might be 310 due to the broader definition of acquisition of resistance as it is more sensitive to resistance 311 changes in the microbial community. If a treatment is targeted against a specific pathogen, e.g. a 312 gram-positive bacterium, other bacteria of the microbiota are exposed to the treatment as well. 313 Some bacteria of the microbiota might be more intrinsically resistant against the administered

314 antibiotics, e.g. a gram-negative bacterium, and are therefore more likely to develop resistance. 315 With acquisition of resistance, we might detect such effects. 316

6.1.7.All resistances not only against administered antibiotics

317 Antibiotic resistances can be acquired by plasmids, which in a clinical context often confer 318 resistances against multiple antibiotics (59-61). Therefore, we aimed to test, whether a higher 319 number of antibiotics also leads to resistance against a higher number of antibiotics, considering 320 both resistances of antibiotics that were administered and ones that were not. For acquisition of 321 resistance, we only identified seven studies that measured resistances also against non-322 administered drugs. Only three of those studies have non-zero events. For de novo emergence of 323 resistance, we identified four studies measuring resistances against non-administered antibiotics, 324 were two of them have non-zero events in both treatment arms. Due to the small number of 325 studies identified and even smaller number of studies having non-zero resistance events, we only 326 present the estimates of the resistances against non-administered antibiotics (sections 9.6 and 327 9.7). 328

6.1.8. Only resistances of antibiotics common to treatments arms

329 To estimate how the same antibiotics performed in the different treatment arms we 330 performed a subgroup-analysis only considering resistance against antibiotics common to both 331 treatment arms. For both main outcomes we observed that if we only consider resistances of 332 common antibiotics the treatment arm with the higher number of antibiotics showed a benefit 333 (acquisition of resistance: pooled OR 0.39, 95% CI 0.18 – 0.81; l^2 =76%, table S3; emergence of 334 resistance: pooled OR 0.32, 95% CI 0.16 – 0.66; I^2 =59% table S4). Consequently, we can 335 conclude that for a specific antibiotic less resistances will develop in a treatment arm with a 336 higher number of antibiotics.

337 As the studies included in our meta-analysis often did not quantify the resistance outcome 338 for all antibiotics administered in a treatment arm it is harder to assess the full resistance burden 339 of the antibiotic treatments systematically. One could argue that due to the higher number of 340 antibiotics given in one treatment arm, one would also observe in total a higher resistance burden 341 in that arm. This possible effect could be magnified dependent on the potency of antibiotics. If a 342 treatment arm is a combination of a low potency antibiotics, one might expect a higher chance of 343 resistance. The results of this sub-group analysis highlight once more that a systematic 344 exploration of resistance development in RCTs is important for a better understanding of 345 resistance development during treatment and that the identity of the administered antibiotics 346 might play an important role. 347

6.1.9. Age of antibiotics since conduction of the trial

348 The prevalence of antibiotic resistance affects the treatment success. If resistance before 349 treatment is frequent in the population, then this increases the likelihood that the prescribed 350 antibiotic treatment fails for any patient. We collected data on the year the admission of patients 351 for the individual studies started and the year antibiotics became available. With the naive 352 assumption that the longer the antibiotic has been available before the study was conducted, the 353 higher is its resistance prevalence within the population. This assumption has its weaknesses as 354 antibiotics are used with different intensities over the years and their local pattern of use might 355 vary. However, such data are more difficult to retrieve. Hence, the years an antibiotic was 356 available until the trial started is a simple first approximation to investigate resistance prevalence.

357 If the studies did not state the year the trial started, we extracted the publication year. For 358 the availability of antibiotics, we used the older of the two dates available on DrugBank (62) and 359 DrugCentral (63) (DrugBank: marketing start, DrugCentral: approvals).

360 In the following we present the subgroup analyses, where we classify in which comparator 361 arm the youngest antibiotic is administered. We did not detect a harm or benefit of using a higher 362 or lower number of antibiotics when stratifying, and observed in all subgroup analyses at least a 363 substantial amount of heterogeneity (table S3, table S4).

364 Furthermore, we performed subgroup analyses stratifying according to the mean age of 365 antibiotics in a treatment arm, and the oldest antibiotic of the treatment arm. For those analyses 366 we also did not identify a difference of using a higher number of antibiotics over fewer. It could be 367 that our approximation is too simplified to estimate the potential effect.

6.1.10. No antibiotics common to treatment arms

369 In the main analyses we presented the estimates for all studies, and studies, which 370 administered at least one antibiotic common to the treatment arms. Here in the supplement we 371 present the resistance estimates for less comparable treatments, i.e. for studies, whose treatment 372 arms had no antibiotics in common. For those studies we observed for both main outcomes a 373 trend favouring the treatment arm with fewer antibiotics (acquisition of resistance: pooled OR 374 4.73, 95% CI 2.14 – 10.42; l²=37%, table S3; de novo emergence of resistance: pooled OR 3.54, 375 95% CI 0.91 – 13.75; I²=38%, table S4). The benefit was for acquisition of resistance clear, and 376 for de novo emergence of resistance not. The result that if the treatment arms had no antibiotics 377 in common a lower number of antibiotics performed better than a higher number of antibiotics 378 could be due to different potencies of antibiotics or resistance prevalences. Further, there could 379 be a bias to combine less potent antibiotics or antibiotics with higher resistance prevalence to 380 ensure treatment efficacy, which could lead to higher chances to detect resistances in the 381 treatment arm with higher number of antibiotics, e.g. by selecting pre-existing resistance (see 382 also section 6.1.9). This highlights once more that the identity of antibiotics may play an important 383 role in determining whether combining antibiotics is beneficial or not with respect to resistance 384 development.

6.1.11. Systematic testing of the whole study population

385 386 In our protocol we predefined that we would perform a sub-group analyses based on 387 whether the resistance data were systematically available for the whole study population or just a 388 subset of patients. All our included studies attempted to measure resistance data for the whole 389 study population. In some cases, more information on resistance development was reported than 390 what we could use. In those cases, it was impossible to distinguish how many patients were 391 evaluable for the resistance outcomes, and/or how many patients developed resistances. In 392 summary, we always obtained data for the whole study population, except of the missing data 393 cases, but nevertheless we could not process all information given due to the way it was 394 reported. The influence of missing data is assessed in the risk of bias assessment (section 3), 395 and the corresponding sensitivity analyses (section 4.2).

396 6.2. Post-hoc subgroup analyses

6.2.1.Additional administration of antibiotics

398 During our selection process of studies, we realised that some studies allowed the addition 399 of further antibiotics to the assigned treatments, if necessary, whereas others explicitly stated no 400 other antibiotics than the assigned ones are given during the treatment phase. For a large 401 proportion of all included studies, we could not extract whether additional antibiotics were allowed 402 or not (62%). As we cannot rule out that in those studies no additional antibiotics were 403 administered, we decided to include studies where additional antibiotics are allowed. To check 404 the impact of this decision we performed a sub-group analyses for those studies, where 405 information of administration of additional antibiotics was given. We identified 12 studies, which 406 allowed the administration of additional antibiotics, but only at most seven studies could be 407 included in the statistical analyses as the other trials reported zero cases in both treatment arms 408 (14, 17, 19, 23, 30) (tables S5, S6). We identified three studies explicitly excluding additional 409 antibiotics, however the statistical analyses is based on two studies as one reported zero cases in 410 both treatment arms (16) (tables S5, S6). Therefore, the impact of allowing the administration of 411 additional antibiotics, if necessary, on our overall estimates was difficult to infer.

412

397

413 **Table S5.** Summary of the results of the post-hoc sub-group analyses for the outcome acquisition 414 of resistance. Note that the listing of eligible studies also includes studies reporting zero cases in 415 both treatment arms and were therefore not included in the statistical analysis.

Sub-group Analysis	OR (95% CI)	Study heterogeneity (<i>I</i> ² ; τ ²)	Eligible studies
Additional administration of antibiotics:			
Allowed	1.18 (0.70-1.97)	16%; 0.07	(12, 14, 17, 19, 23, 24, 30, 36-39, 46)
Prohibited	0.19 (0.04-0.98)	57%; 0.79	(16, 22, 47)
Pre-resistance against non-administered			

antibiotics required at study inclusion:			
Required	1.08 (0.57-2.05)	15%; 0.07	(12, 14, 19, 33, 36-38, 44)
No	1.25 (0.61-2.55)	79%; 2.22	(6-11, 13, 15-18, 20-32, 34, 35, 39-43, 45-47)
Way of antibiotic administration:			
Orally	1.18 (0.44-3.15)	78%; 2.70	(6-8, 10, 13, 18, 22, 23, 25, 26, 28, 31, 32, 35, 40, 41, 43-47)
Intravenously	1.83 (0.67-5.00)	66%; 0.90	(12, 14, 16, 17, 21, 24, 27, 37, 38, 42)
Different ways of administration in the treatment arms	1.51 (0.67-3.39)	1%; 0.01	(11, 20, 34, 36)

417 **Table S6.** Summary of the results of the post-hoc sub-group analyses for the outcome *de novo*

418 emergence of resistance. Note that the listing of eligible studies also includes studies reporting

419 zero cases in both treatment arms and were therefore not included in the statistical analysis.

Sub-group Analysis	OR (95% CI)	Study heterogeneity $(I^2; \tau^2)$	Eligible studies
Additional administration of antibiotics:			
Allowed	0.95 (0.59-1.51)	3%; 0.01	(12, 14, 17, 19, 23, 24, 30, 36-39)
Prohibited	0.19 (0.04-0.98)	57%; 0.79	(16, 22, 47)
Pre-resistance against non-administered antibiotics required at study inclusion:			
Required	1.07 (0.53-2.18)	17%; 0.10	(12, 14, 19, 33, 36-38, 44)
No	0.63 (0.23-1.68)	78%; 2.57	(6-10, 13, 15-17, 20-27, 29, 30, 32, 34, 39, 42, 43, 47)
Way of antibiotic administration:			
Orally	0.37 (0.11-1.23)	69%; 1.96	(6-8, 10, 13, 22, 23, 25, 26, 32, 43, 44, 47)
Intravenously	1.82 (0.64-5.18)	66%; 0.90	(12, 14, 16, 17, 21, 24, 27, 37, 38, 42)
Different ways of administration in the treatment arms	2.12 (0.35-12.79)	1%; 0.01	(20, 34, 36)

⁴²⁰

421 422

6.2.2.Pre-resistance against non-administered antibiotics

423 Some of the studies we included were focused on the treatment of resistant pathogens. 424 Therefore, we tested whether carriage of resistance against non-administered antibiotics might 425 affect the development of resistance against administered antibiotics. We identified eight studies 426 requiring pre-resistance, of which five had non-zero events in both treatment arms. For both 427 studies requiring pre-resistance and no pre-resistance, we could not identify a trend favouring 428 more or less antibiotics (tables S5, S6). As multi-drug resistance is an increasing concern it is 429 important to understand if the optimal treatment strategy for pre-resistant pathogens might differ 430 from the one of sensitive pathogens. However, the data of our meta-analysis are not sufficient to 431 answer this question. 432

6.2.3.Way of antibiotic administration

433 The way how antibiotics are administered, e.g. intravenously (IV) or orally, could also impact 434 the development of antibiotic resistance due to different pharmacokinetics and potential differing 435 antibiotic bioavailability (64). Therefore, we stratified our studies according to the way antibiotics 436 were administered: orally, or IV in both treatment arms, or the way of administration differed in the 437 treatment arms. We could not identify a harm or benefit in the sub-group analyses of using a higher or a lower number of antibiotics (tables S5, S6). 438

439 7. Meta-regressions and multi-model inference

440 Additionally, to the subgroup analyses we also performed meta-regressions for the exploration of 441 the importance of factors potentially affecting our main outcomes. For the meta-regression

442 models we used the conventional random effects model (model 1 in Jackson et al (48)) due to

- 443 convergence issues with model 4 and since our sensitivity analysis of the main outcomes showed 444 typically robustness to the model choice (section 4). With performing meta-regressions, we were
- 444 typically robustness to the model choice (section 4). With performing meta-regressions, we were 445 able to include continuous covariables such as treatment length, and by multi model inference we
- 445 able to include continuous covariables such as treatment length, and by multi model interence we 446 could obtain parameter estimates averaged over a set of models. The set of possible models was
- 447 restricted to meta-regression models with up to two covariables and no interaction terms to avoid
- 448 overfitting. We performed multi-model inference with the R package MuMIn (version 1.46) (65).
- 449 For the multi-model inference all meta regression models of the set of possible models were
- simulated. Following a model selection approach using the Akaike information criterion (AIC)
 model, the AIC value for each model was calculated. The AIC is a measure of fit, which is based
 on the log-likelihood function, and the number of unknown model parameters. Smaller AIC values
- are assigned to better model fits. In addition to the AIC value, we calculated the AIC differences (Δ AIC) between each model and the model with the lowest AIC value. With Δ AIC we calculated the Akaike weights, which can be interpreted as the probability a model is the best of the given set of models and data. With the full model approach, we then calculated the model averaged coefficients, which are estimates weighted by the Akaike weights and averaged over the whole set of possible models (full model average). For the interested reader further, detailed information
- 459 can be found in literature about multi-model inference (66-68).
- The covariables we considered for the meta-regression included: (i) administration of antibiotics common to the treatment arms, (ii) required comorbidity status at study inclusion, (iii) the year difference between the youngest antibiotic in the treatment arm with a lower number of antibiotics and the youngest in the treatment arm with a higher number of antibiotics, (iv) the treatment length, (v) the length of study/resistance follow up, (vi) gram status of bacteria with resistance measurements, and (vii) the number of antibiotics administered
- measurements, and (vii) the number of antibiotics administered.
 In some cases, the treatment length of the two treatment arms within a study were of different
 length, in those cases we took as the treatment length covariable the average treatment time of
 both treatment arms. As the treatment times between treatment arms did not vary a lot, we did
- not explore those differences further. Furthermore, we wanted to consider the age of antibiotics
 since the conduction of a trial. There are several ways of how to implement this as a covariable.
 We decided to take the difference of the youngest antibiotics in both treatment arms, as we
 expected that novel antibiotics are more likely to be tested in the treatment arm with lower
- 473 antibiotics.
- For our multi-model inference, we excluded the variables considering whether a study was
- 475 conducted in an ICU, and whether additional drugs were administered as we could not confidently 476 obtain information regarding those variables for more than half of the studies. Due to a high
- obtain information regarding those variables for more than half of the studies. Due to a high
 correlation between the administration of antibiotics common to the treatment arms and same
- 478 dosage (acquisition of resistance: 0.95, *de novo* emergence of resistance: 0.91) we excluded the 479 variable same dosage from the meta-regressions.
- 480 Our multi model inference showed that for acquisition of resistance the most important covariable 481 to include in a meta-regression model to explain some of the observed heterogeneity was
- 482 whether antibiotics common to the treatments were used or not (table S7). This is in line with our
- 483 sub-group analysis performed (main text figure 3B). By including the information whether at least
- 484 one antibiotic was common to both treatment arms in a meta-regression, we could find a
- 485 decrease in the estimated heterogeneity (l^2 =59, no-meta-regression: l^2 =77), but nevertheless the 486 heterogeneity remains substantial (table S8). Furthermore, we could confirm once more that a
- 487 lower number of antibiotics performs better, if in the treatment arms no common antibiotics are
 488 used (tables S7, S8). For *de novo* emergence of resistance, the multi model inference did not
- 489 show any significant covariables (table S9).
- 490 Overall, this does not necessarily mean that any of the covariables are not impacting the outcome
- 491 of resistance development significantly, but since most studies were underpowered (main text
- 492 figure 2 B) there is the possibility that we are missing important signals.
- 493

494 Table S7. Overview of the model averaged coefficients obtained by the multi-model inference for

- 495 the main outcome acquisition of resistance. Significant model estimates are displayed in a bold
- 496 font.

Model-averaged coefficients (full- average)	Estimated	Standard error	z value	Pr(> z)
Intercept	0.73	1.69	0.60	0.54
Length of follow-up	1.00	1.00	0.46	0.65
Treatment length	0.99	0.01	0.77	0.43
1 vs. 3 antibiotics	0.78	2.19	0.31	0.75
2 vs. 3 antibiotics	1.16	2.16	0.19	0.85
Antibiotics in common: no	5.67	1.89	2.73	0.01
Comorbidity: yes	1.35	1.77	0.53	0.60
Gram positive and negative bacteria	1.52	1.91	0.65	0.52
Gram positive bacteria	1.08	2.07	0.11	0.91
Year difference of youngest antibiotics	1.00	1.01	0.15	0.88

- 498 Table S8. Model output for a meta-regression for acquisition of resistance including as a
- 499 covariable, whether at least one antibiotic was in common in the treatment arms. Significant
- 500 model estimates are displayed in a bold font.

	OR (95% CI)	z value	Pr(> z)	Study heterogeneity (I^2 ; τ^2)
Intercept	0.63 (0.33-1.21)	-1.39	0.17	59%; 0.90
Antibiotics	5.86 (2.05-16.76)	3.30	<0.01	
common: no				

501

502 Table S9. Overview of the model averaged coefficients obtained by the multi-model inference for 503 the main outcome de novo emergence of resistance.

Model-averaged coefficients (full- average)	Estimated	Standard error	z value	Pr(> z)
Intercept	2.22	2.42	0.90	0.37
Length of follow-up	0.99	1.01	0.73	0.46
Treatment length	1.00	1.01	0.41	0.68
2 vs. 3 antibiotics	1.29	2.51	0.28	0.78
Antibiotics in common: yes	0.32	2.66	1.16	0.25
Comorbidity: yes	1.40	2.03	0.47	0.64
Gram positive and negative bacteria	1.45	2.23	0.47	0.64
Gram positive bacteria	1.16	1.98	0.21	0.83
Year difference of youngest antibiotics	0.99	1.02	0.30	0.72

504 505

506 8. Statistical power

507 8.1. Adequate treatment arm size

508 Resistance development is a rare event and therefore differences in resistance development are 509 difficult to detect in small population sizes. To illustrate this, we calculated how much participants

510 would have needed to be included per treatment harm in order to detect whether a higher number 511

- of antibiotics would half the odds of occurrence of resistance and compared it to the actual
- 512 number of participants (figure S6). For the calculations we assumed a power of 80% and used for

- 513 each trial the upper confidence interval for the probability of resistance development in the
- 514 treatment arm with the lower number of antibiotics. The confidence interval was determined with

515 Bayesian inference.

516



517

Fig. S6. The calculated adequate treatment arm size for each study assuming to detect an odds
ratio of 0.5 with 80% power in comparison to the actual treatment arm sizes. The power
calculations were performed using the upper confidence interval for the binomial probability of the
treatment arm with less antibiotics.

522

523 524

8.2. Trial sequential analysis

525 It is expected that pooling data from several RCTs results in a high level of evidence. 526 Nevertheless, meta-analysis might lead to inconclusive results or even misleading ones as meta-527 analyses can also suffer from low statistical power (69). Therefore, we performed for our two 528 main outcomes a trial sequential analysis (TSA), using the TSA tool version 0.9.5.10 Beta 529 (Copenhagen: The Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016) to 530 assess how strong and sufficient the evidence of our overall analyses is. For both outcomes the 531 TSA supports that the existing evidence on resistance development is not sufficient and 532 conclusive, as the trial sequential monitoring boundary is not crossed by the Z-curve in any of the 533 cases, nor is the required sample size reached (figure S7). For the TSA calculations we used 534 resistance incidence rate per treatment arm, which we calculated by averaging the incidence 535 rates of all included studies (per outcome). For interested readers technical details of the TSA 536 can be found elsewhere (69, 70). The TSA analysis is an additional analysis, which was not 537 predefined in our study protocol.





Fig. S7. TSA output using 80% power, and 5% significance to detect a relative odds reduction of
 50%: A) acquisition of resistance. B) *de novo* emergence of resistance. No sufficient evidence on
 development of resistance is supported, since the Z-curves do not cross the monitoring nor the
 futility boundaries, and the required sample size is not reached.

545 9. Secondary Outcomes

546 In the evaluation of an optimal antibiotic treatment strategy many factors play a role besides the 547 potential spread of antibiotic resistance and therewith the future potential to treat infections 548 successfully. One important factor, which is naturally the focus of clinical research, is the 549 wellbeing of the patient receiving antibiotic treatment. Antibiotic combination therapy is often 550 associated with a higher medical burden for the treated patient, e.g. through a higher risk of 551 toxicity (71). To present are more comprehensive evaluation of antibiotic combination therapy, we 552 systematically summarised the following outcomes as an indication for the wellbeing of the 553 treated patient: (i) All-cause mortality, (ii) mortality attributable to infection, (iii) treatment failure, 554 (iv) treatment failure due to a change of resistance against the study drugs, and (v) proportion of 555 patients with alterations to the treatment due to adverse events. Additionally, we collected data on 556 acquisition, and de novo emergence of resistance against non-administered antibiotics to further 557 assess the risk of resistance spread, which might affect future treatment success. Overall. we did 558 not find any indication of a difference for any of these evaluation metrics of combining a higher 559 number of antibiotics in comparison to less as presented below.

9.1. All-cause mortality

560 561 We extracted the number of patients that died in a study as reported. We did not identify a 562 mortality difference of using a higher number of antibiotics opposed to less (figure S8). One must 563 consider that the estimated pooled OR 0.98 (95% CI 0.79 - 1.21) was based on several RCTs 564 with different sources of potential heterogeneity, which we did not account for in our statistical 565 analysis of secondary outcomes. Nevertheless, the heterogeneity in our random effects model for 566 all-cause mortality could be classified as unimportant ($l^2=11\%$). In previously conducted meta-567 analyses evaluating antibiotic combination therapy mortality was often the main outcome, but the 568 inclusion criteria were less broad, constrained to specific diseases, pathogens, or particular 569 antibiotic combinations. The results of those meta-analyses do not easily generalize to one 570 overall trend, but rather highlight that sub-analyses accounting for specific infections and 571 antibiotic comparisons might be important as we found for our main outcomes of resistance 572 development (72-74). Nevertheless, we found in line with most previous meta-analyses no clear 573 harm or benefit of combining a higher number of antibiotics or less with respect to all-cause 574 mortality.

	Anti	biotics		
Study / subgroup	Less (n/N)	More (n/N)	OR (95% CI)	OR (95% CI)
Jacobs 1993	1 / 45	0 / 44		0.33[0.01, 8.41]
Markowitz 1992 ²⁷	1 / 115	0 / 113	⊢−−−−−− 1	0·34 [0·01, 8·34]
Chaisson 1997 ⁸	34 / 55	20 / 51	⊢_ ∎4	0.40 [0.18, 0.87]
May 1997 ²⁹	19 / 43	15 / 43	⊢_ ∎1	0.68 [0.28, 1.61]
Dubé 1997 ¹³	44 / 46	46 / 49	⊢	0·70 [0·11, 4·37]
Pogue 2021 ³⁷	92 / 213	77 / 210	⊢ ∎÷1	0.76 [0.52, 1.12]
Pujol 2021 ³⁸	22 / 81	18 / 74	⊢ ∎1	0.86 [0.42, 1.78]
Durante–Mangoni 2013 ¹⁴	45 / 105	45 / 104	⊢ ∎1	1.02 [0.59, 1.76]
Gibson 1989 ¹⁷	5 / 52	5 / 50	÷4	1.04 [0.28, 3.85]
Fournier 1999 ¹⁵	11 / 16	13 / 18	⊧i∎i	1·18 [0·27, 5·18]
Rubinstein 1995 ³⁹	31 / 306	33 / 274	⊨∎→	1.21 [0.72, 2.04]
Paul 2015 ³⁶	13 / 117	19 / 135	⊢	1.31 [0.62, 2.78]
Dickstein 2020 ¹²	86 / 196	94 / 185	i H ∎ -1	1.32 [0.88, 1.98]
Dekker 1987 ¹¹	2 / 28	3 / 28	F	1.56 [0.24, 10.14]
Harbarth 2015 ¹⁹	2/75	4 / 75	⊢ I	2·06 [0·37, 11·58]
Bender 1979 ⁶	0 / 20	1 / 19	F	3·32 [0·13, 86·75]
Gerecht 1989 ¹⁶	0 / 24	3 / 22	—	— 8·79 [0·43, 180·63]
Mc Carty 1988 ³⁰	0 / 8	0/9		
Total (95% Cl)			•	0.98 [0.79, 1.21]
Heterogeneity: $\tau^{-}=0.02$; $\Gamma^{-}=$:11%	Favors a high	er number of antibiotics Favors fewer antibiotic	S
		0	0.02 0.14 1 7.39 54.6	403·43

578

579 **9.2.** *Mortality attributable to infection*

580 Besides all cause-mortality we also extracted the number of deaths that the respective study 581 authors attributed to the infection treated. As for all-cause mortality our estimate for mortality 582 attributable to infection indicated no difference between treating with a higher number of 583 antibiotics in comparison to less (pooled OR 1.05, 95% Cl 0.64 – 1.71; figure S9), and the model 584 heterogeneity could also be classified as unimportant (l^2 =12%).

⁵⁷⁷ **Fig. S8.** Forest plot of all-cause mortality.

Antibiotics							
Study / subgroup	Less (n/N)	More (n/N)		OR (9	95% CI)		OR (95% CI)
Harbarth 2015 ¹⁹	1 / 75	0 / 75			1		0·33 [0·01, 8·20]
Cometta 1994 ⁹	18 / 142	13 / 138		⊢ ∎			0·72 [0·34, 1·52]
Durante-Mangoni 2013 ¹⁴	28 / 105	22 / 104		⊨∎			0·74 [0·39, 1·40]
Winston 1986 ⁴⁵	3 / 36	4 / 30			.		1·69 [0·35, 8·24]
Rubinstein 1995 ³⁹	8 / 306	14 / 274		ŀ	 .		2.01 [0.83, 4.86]
Dekker 1987 ¹¹	0 / 28	1 / 28		ŀ			3.11 [0.12, 79.64]
Gibson 1989 ¹⁷	1 / 52	3 / 52		H			3.12 [0.31, 31.05]
Mc Carty 1988 ³⁰	0/8	0/9					
Total (95% Cl) Heterogeneity: τ²=0·05; l²=	:12%				•		1.05 [0.64, 1.71]
Favors a higher number of antibiotics Favors fewer antibiotics							
			Ι			Ι	
		0	0.02	0.14	1 7.39	54·6	403.43

587 **Fig. S9.** Forest plot of mortality attributable to infection.

588

589 **9.3.** *Treatment failure*

590 We extracted the number of treatment failures in each treatment arm if treatment failure was 591 explicitly defined or classified by the study authors. As the selection of studies for this meta-592 analysis was not restricted to one specific pathogen, or condition requiring antibiotic treatment, 593 we expected a variety of different reasons for the employment of antibiotics. Out of practicality 594 and to account for the different conditions treated, we decided not to pre-define our own criteria 595 for treatment failure for each condition, but rather use the study's authors interpretation of 596 treatment failure (table S10). 597 Our estimate gave no indication for a difference in treatment failure when treating with a higher

597 Our estimate gave no indication for a difference in treatment failure when treating with a higher 598 number of antibiotics in comparison with a lower number of antibiotics if treatment failure was 599 considered (pooled OR 0.98, 95% CI 0.66 – 1.47; figure S10). However, we observed a

substantial amount of heterogeneity in our model ($l^2=74\%$), which might indicate that for some

bacterial conditions or some antibiotic combinations there might be a difference.

Table S10. Overview of different treatment failure definitions.

Study	Definition of treatment failure given by the study authors
Cometta et al. (1994) (9)	Lack of improvement of primary infection, development of a sepsis syndrome or septic shock during treatment, superinfection
Durante-Mangoni et al. (2013) (14)	No improvement of clinical conditions by day 21 or worsening of the condition at any time, given persistently positive <i>Acinetobacter baumannii</i> cultures
Gerecht et al. (1989) (16)	Continued presence of infecting organism(s) in bile cultures, with persistent indications of cholangitis, or superinfection, or the presence of new infecting organism(s) during or at the end of antibiotic treatment, with indications of cholangitis, or emergence of an infecting organism(s) resistant to gentamicin or mezlocillin during treatment, with indications of cholangitis, or emergence of an infecting organism(s) resistant to gentamicin or mezlocillin during treatment, with indications of cholangitis, or relapse, or recurrence of indications of cholangits, with the original infecting organism(s) present in cultures of bile or blood within eight weeks after treatment, or death due to uncontrolled infection.
Haase et al. (1984) (18)	The persisting presence of the pretherapy infecting organism, with or without pyuria, during treatment.
Hartbarth et al. (2015) (19)	No improvement or worsening in the clinical condition, or a change of the assigned therapy at any time, or death.
Jacobs et al. (1993) (24)	No apparent response to therapy and no definitive identification of an alternative etiology that would explain this lack of response.
Markowitz et al. (1992) (27)	Persistence of septic pulmonary emboli, persistence of positive blood or deep tissue cultures, or relapse after the end of presumably adequate treatment.
May et al. (1997) (29)	Treatment failure was defined as all other situations than success, whereas the primary determinants of success were as follows: patient living, either not fever or a reduction of \geq 1 °C in initial body temperature, and a blood culture negative for <i>M. avium</i>
Parry et al. (2007) (35)	Continuing fever with at least one other typhoid-related symptom for more than seven days after the start of treatment, or a required change in therapy due to the development of severe complications during treatment (severe gastrointestinal bleeding, intestinal perforation, visible jaundice, myocarditis, pneumonia, renal failure, shock, or an altered conscious level)
Paul et al. (2015) (36)	Treatment failure at seven days was defined as a composition of death, persistence of fever, persistence of hypotension, non-improving Sequential Organ Failure Assessment score, or persistent bacteraemia on day seven.
Pogue et al. (2021) (37)	Clinical failure was defined by meeting any of the following criteria: death either during therapy or within 7 days after; receipt of rescue therapy for the trial pathogen within 7 days after treatment, exclusion from the trial due to an adverse event considered related to trial treatment; bacteremia more than 5 days after the begin of therapy for patients with blood stream infections; or failure to improve or worsening of oxygenation by the end of trial treatment in patients with pneumonia.
Pujol et al. (2021) (38)	No clinical improvement after 3 days of therapy, persistent MRSA bacteraemia at day 7 or later, early discontinuation of therapy due to adverse events or based on clinical judgment, recurrent MRSA bacteraemia before or at test of cure, missing blood cultures at test of cure, and/or death due to any cause before test of cure.
Rubinstein et al. (1995) (39)	Use of a new antibiotic due to a worsening in clinical condition, isolation of resistant organism, or

|--|

Antibiotics							
Study / subgroup	Less (n/N)	More (n/N)		OR (9	5% CI)		OR (95% CI)
Jacobs 1993 ²⁴	13 / 45	4 / 44		⊢_∎1			0·25 [0·07, 0·83]
Parry 200735	23 / 63	26 / 124		⊢ ∎1	• • •		0.46 [0.24, 0.90]
May 1997 ²⁹	34 / 43	29 / 43		⊢			0·55 [0·21, 1·45]
Durante-Mangoni 2013 ¹⁴	29 / 105	19 / 104		⊦-∎-			0.59 [0.30, 1.13]
Pujol 2021 ³⁸	47 / 81	34 / 74		⊦_∎_	-1		0.61 [0.33, 1.16]
Cometta 1994 ⁹	29 / 142	19 / 138		⊢-■	-		0.62 [0.33, 1.17]
Pogue 2021 ³⁷	119 / 184	110 / 190		⊢∎	÷		0.75 [0.49, 1.14]
Harbarth 2015 ¹⁹	19 / 75	16 / 75		⊦			0.80 [0.37, 1.71]
Paul 2015 ³⁶	32 / 117	51 / 135		I			1.61 [0.94, 2.75]
Walsh 1993 ⁴⁴	15 / 45	23 / 49		F			1.77 [0.77, 4.08]
Rubinstein 1995 ³⁹	34 / 306	51 / 274			⊢∎⊣		1.83 [1.15, 2.92]
Haase 1984 ¹⁸	0 / 22	1 / 21		H		1	3·29 [0·13, 85·44]
Gerecht 1989 ¹⁶	4 / 24	13 / 22			⊢ ■		7·22 [1·84, 28·40]
Markowitz 1992 ²⁷	1 / 64	6 / 50				1	8·59 [1·00, 73·88]
Total (95% CI) Heterogeneity: τ ² =0·38; I ² =	=74%	Favors a high	er numbe	r of antibiotics	Favors fewer a	antibiotics	0.98 [0.66, 1.47]
		. avoio a nign					
			0.02	0.14	1 7.39	54·6	403·43

606 **Fig. S10.** Forest plot of treatment failure.

607

608 9.4. Treatment failure due to a change of resistance against the study drugs

We could only extract information for treatment failure due to a change of resistance against the study drugs from three out of the 42 studies. As one of the studies had zero-events in both treatment arms our statistical summary estimate was only based on two studies and should therefore be interpreted with caution. Nevertheless, as for treatment failure we did not identify a difference of using a higher number of antibiotics in comparison to less when considering treatment failure due to a change of resistance against the study drugs (pooled LOR 0.61, 95% CI 0.29 – 1.28; l^2 =1%; figure S11).



618 **Fig. S11.** Forest plot of treatment failure due to a change of resistance against the study drugs.

619

620 9.5. Alterations of the prescribed treatment due to adverse events

To get an indication how well the treatments were tolerated by the patients we extracted data on alterations of the prescribed treatment due to adverse events. We did identify benefit of using a lower number of antibiotics in comparison to a higher one. The heterogeneity in the random effects model could be classified as unimportant (pooled OR 1.61, 95% Cl 1.12 – 2.31; I^2 =5%; figure S12).

Antibiotics							
Study / subgroup	Less (n/N)	More (n/N)		OR (9	95% CI)		OR (95% CI)
Schaeffer 198140	1 / 20	0 / 20	H				0.32 [0.01, 8.26]
Hoepelman 1988 ²¹	1 / 47	0 / 46					0.33 [0.01, 8.40]
Jo 2021 ²⁵	2/10	0/3					0.49 [0.02, 12.93]
Dubé 1997 ¹³	29 / 46	30 / 49			: =1		0.93 [0.40, 2.12]
Macnab 1994 ²⁶	10 / 173	8 / 146		—	: =		0.94 [0.36, 2.46]
Markowitz 1992 ²⁷	3/110	3/112		H	: =1		0.98 [0.19, 4.97]
Miehlke 1998 ³²	1 / 74	2/81		H			1.85 [0.16, 20.81]
Pogue 2021 ³⁷	12/213	21 / 210			i <u>-</u> ∎1		1.86 [0.89, 3.89]
Dickstein 2020 ¹²	2 / 196	4 / 208		—			1.90 [0.34, 10.50]
May 1997 ²⁹	21 / 67	35 / 67			∎1		2·40 [1·18, 4·85]
Rubinstein 1995 ³⁹	1 / 306	3 / 274					3·38 [0·35, 32·65]
Pujol 2021 ³⁸	4 / 83	13 / 77			⊢− ∎−−1		4.01 [1.25, 12.90]
Fournier 1999 ¹⁵	0 / 16	0 / 18					
Gibson 1989 ¹⁷	0 / 52	0 / 50					
Parras 1995 ³³	0 / 43	0 / 41					
Total (95% CI)					•		1.61 [1.12 2.21]
Heterogeneity: $\tau^2 = 0.02$; l^2	=5%				-		
		Favors a high	er number	r of antibiotics	Favors fewer a	ntibiotics	
		0	0.02	0.14	1 7.39	54·6	

628 **Fig. S12.** Forest plot of alterations of the prescribed treatment due to adverse events.

629

630 9.6. Acquisition of resistance against non-administered antibiotics

631 There are several ways of how bacteria may get resistant against antibiotics, one of them is 632 through acquiring antibiotic resistance plasmids. Clinically relevant plasmids often confer 633 resistance against multiple antibiotics (59-61). Therefore, one might expect if a patient is treated 634 with a higher number of antibiotics the chances increase to acquire multidrug resistant plasmids 635 that confer resistances to antibiotics that are not part of the current treatment. In addition, one 636 could expect, that the chances for cross resistances increase, i.e., the obtained resistance 637 confers resistances to several antibiotics, if a higher number of antibiotics is administered. To 638 check this reasoning, we extracted the data for acquisition, and *de novo* emergence of resistance 639 against non-administered antibiotics. 640 For seven studies we extracted the data for acquisition of resistance against non-administered

antibiotics, but we could only use three of them for our statistical analyses as the other studies

had zero events in both treatment arms. As the statistical analysis was only based on three

- studies and the model showed moderate to substantial heterogeneity ($l^2=60\%$) our estimate might
- 644 not be sufficient to confidently give an indication. The pooled LOR of our random effects model

- 645 suggested no difference in using a higher number of antibiotics in comparison to less to reduce
- 646 acquisition of resistance against non-administered drugs (OR 0.39, 95% CI 0.02 - 8.48; figure S13).
- 647
- 648

	Antib	iotics					
Study / subgroup	Less (n/N)	More (n/N)		OR (9	95% CI)		OR (95% CI)
Dekker 1987 ¹¹	4 / 28	0/28 ⊢					0.10 [0.00, 1.86]
Paul 2015 ³⁶	1/117	0 / 135	 				0·29 [0·01, 7·10]
Smith 1999 ⁴²	0 / 30	3 / 40				1	5·69 [0·28, 114·52]
Gibson 1989 ¹⁷	0/8	0 / 13					
Haase 1984 ¹⁸	0/21	0 / 21					
Markowitz 1992 ²⁷	0 / 58	0 / 43					
Walsh 199344	0 / 45	0 / 49					
Total (95% CI)	² -60%						0·39 [0·02, 8·48]
Therefore the transformation is the transformation of transformat	-00%	Fourier o bio			Favora favora a	ntibiotico	
		Favors a hig			ravors fewer a		
		0	0.02	0.14	1 7.39	54·6	403·43

- 649
- 650 Fig. S13. Forest plot of acquisition of resistance against non-administered antibiotics.
- 651

652 9.7. De novo emergence of resistance against non-administered antibiotics

653 As for the main outcomes we distinguished between acquisition and de novo emergence of 654 resistance. According to our definition (main text: Methods), de novo emergence of resistance is 655 a subset of acquisition of resistance. For acquisition of resistance against non-administered 656 antibiotics we obtained three studies eligible for the statistical analysis, for de novo emergence 657 only two. Therefore, the estimates need to be taken with consideration. As for acquisition of 658 resistance against non-administered antibiotics there was no indication for a difference of using a 659 higher or a lower number of antibiotics (pooled OR 1.91, 95% CI 0.09 - 39.69; /2=33%; figure 660 S14).



- 663 **Fig. S14.** Forest plot of *de novo* emergence of resistance against non-administered antibiotics.
- 664

665 10. List of contacted authors and reasoning for exclusion of studies included in previous meta-analyses

An overview of authors, that were contacted for clarification of study data, is shown in table S11. In our meta-analysis we excluded some studies that were included in previous meta-analyses focusing on resistance development (72, 75). An overview of those studies and an exclusion reason is given in table S12.

672 **Table S11.** List of studies for which study authors or institutions were contacted. An indication is673 given whether clarifying information was obtained.

Study	Person/Institution contacted	Information sufficient for paper inclusion obtained (yes/no)
Bazolli 1998 (76)	Franco Bazolli	no
Benson 2000(77)	Constance Benson	no

Bochenek 2003 (78)	David Yates Graham; Wieslaw Bochenek	no
Bosso 1988 (79)	John Bosso	no
Bow 1987 (80)	Eric Bow	no
Cruciani 1989 (81)	Mario Cruciani	no
Dalgic 2013 (82)	Nazan Dalgic	no
De Pauw 1985 (83)	Ben de Pauw	no
De Pauw 1987 (84)	Ben de Pauw	no
Dinubile 2005(85)	Mark Dinubile	no
East African/British medical research	Research office of the royal	no
councils 1972 (86)	Brompton & Harefield hospitals	
Frank 2002 (87)	Elliot Frank	no
Gold 1985(88)	Ronald Gold	no
Grossman 1994 (89)	Ronald Grossman	no
Grabe 1986 (90)	Magnus Grabe	no
Guerrant 1981 (91)	Richard Guerrant	no
Heyland 2008 (92)	Daren Heyland	no
Hodson 1987 (20)	Margaret Hodson	no
Hoepelman 1988 (21)	Andy I.M. Hoepelman	no
Jackson 1986 (93)	Mary Anne Jackson	no
Liang 1990 (94)	Raymond Hin Suen Liang	no
McLaughlin 1983 (95)	John McLaughlin	no
Muder 1994 (96)	Robert Muder	no
Padoan 1987 (97)	Rita Padoan	no
Paul 2015 (36)	Mical Paul	yes
Parry 2007(35)	Christopher Parry	yes
Pujol 2021 (38)	Miquel Pujol	yes
Schaad 1997 (98)	Urs Schaad	no
Shawky 2022 (99)	Sherief Bad-Elsalam	no
Sun 2022 (100)	Jia Fan	no

675 Table S12. Table of studies, which were included in previous meta-analyses, but excluded in our 676 677 study. The reason for exclusion is indicated. *In our protocol we stated, that we would include articles in Russian language. However, since VNK, the only Russian speaking author, did not

678 screen all the papers from our systematic search for inclusion, we excluded studies in Russian 679 language.

Study	Inclusion in previous meta-analyses	Reason for exclusion	Identified with our search strategy
Carbon 1987 (101)	Paul 2014(72)	Not accessible via ETH Zurich library services	no
Cone 1985 (102)	Bliziotis 2005(75)	No data on resistance emergence, due to no clear statement how many resistances are measured in the treatment arm with more antibiotics	no
Croce 1993(103)	Bliziotis 2005(75)	No proper randomisation of treatment strategies, i.e., the trial was conducted in different phases	yes
Gribble 1983 (104)	Bliziotis 2005(75)	No fixed treatment, since antibiotics could be substituted during treatment	yes
lakovlev 1998 (105)	Paul 2014(72)	Russian language*	no
Klatersky 1973 (106)	Paul 2014(72)	Not clearly extractable how many patients developed resistance	no
Mandell 1987(107)	Bliziotis 2005(75), Paul 2014(72)	Treatment is not fixed due to alterations of treatment based on the infecting organism	no
Sculier 1982 (108)	Paul 2014(72)	No proper comparison, since the study does not compare per se a different number of antibiotics but	no

		adds an additional way of administration of the same antibiotic	
German and Austrian Imipenem/Cilastatin study group 1992 (109)	Bliziotis 2005(75), Paul 2014(72)	No fixed treatment, as an additional antibiotic was allowed to be administered only in the treatment arm with more antibiotics	no

681 11. Search strategy

682 11.1. PubMed

- 683 ((((((("Bacterial Infections/Drug Therapy"[mesh]) OR "Bacterial Infections/drug effects"[Mesh])
- 684 OR "Bacteria/drug effects"[Mesh]) OR "Bacteria/Drug Therapy"[mesh]) OR (((infection[tiab] OR
- 685 infections[tiab]) AND bacteria*)))) AND ((((((((((((("beta-Lactams/Administration and
- 686 Dosage"[mesh] OR "beta- Lactams/Therapeutic Use"[mesh])) OR
- 687 ("Aminoglycosides/Administration and Dosage"[mesh] OR "Aminoglycosides/Therapeutic
- 688 Use"[mesh])) OR ("Chloramphenicol/Administration and Dosage"[mesh] OR
- 689 "Chloramphenicol/Therapeutic Use"[mesh])) OR ("Glycopeptides/Administration and
- 690 Dosage"[mesh] OR "Glycopeptides/Therapeutic Use"[mesh])) OR ("Rifamycins/Administration
- 691 and Dosage"[mesh] OR "Rifamycins/Therapeutic Use"[mesh])) OR
- 692 ("Streptogramins/Administration and Dosage"[mesh] OR "Streptogramins/Therapeutic
- 693 Use"[mesh])) OR ("Sulfonamides/Administration and Dosage"[mesh] OR
- 694 "Sulfonamides/Therapeutic Use"[mesh])) OR ("Tetracyclines/Administration and Dosage"[mesh]
- 695 OR "Tetracyclines/Therapeutic Use" [mesh])) OR ("Macrolides/Administration and Dosage" [mesh]
- 696 OR "Macrolides/Therapeutic Use"[mesh])) OR ("Oxazolidinones/Administration and
- 697 Dosage"[mesh] OR "Oxazolidinones/Therapeutic Use"[mesh])) OR
- 698 ("QUINOLONES/Administration and Dosage"[mesh] OR "QUINOLONES/Therapeutic
- 699 Use"[mesh])) OR ("Lipopeptides/Administration and Dosage"[mesh] OR
- 700 "Lipopeptides/Therapeutic Use"[mesh])) OR ("Anti-Bacterial Agents/Administration and
- 701 Dosage"[mesh:noexp]))) OR "Anti-Bacterial Agents/Therapeutic Use"[mesh:noexp]) OR "Anti-
- 702 Bacterial Agents/Therapy"[mesh:noexp]) OR antibiotic*[tiab])) AND ((((((("Drug Therapy,
- 703 Combination"[mesh:noexp]) OR "drug combinations"[mesh:noexp]) OR "trimethoprim,
- 704 sulfamethoxazole drug combination"[mesh:noexp]) OR "Drug Synergism"[mesh:noexp]))) OR
- 705 (combination[tiab] AND (therapy[tiab] OR therapies[tiab]))) OR combinationtherap*[tiab])) AND
- 706 ((("Drug Resistance, Bacterial"[Mesh]) OR "Drug Resistance, Microbial"[Mesh:noexp]) OR
- 707 resistan*[tiab]))) NOT (((("Complementary Therapies"[Mesh]) OR "Plant Extracts"[Mesh]) OR
- 708 bismuth[tiab]) OR "Bismuth"[Mesh]))) AND "Controlled Clinical Trial"[Publication Type] 709

11.2. CENTRAL

- 710 #1 MeSH descriptor: [Bacterial Infections] explode all trees and with gualifier(s): [drug therapy -711 DT1
- 712 #2 MeSH descriptor: [Bacteria] explode all trees and with gualifier(s): [drug effects -
- 713 #3 ((infection):ti.ab.kw OR (infections):ti.ab.kw) AND bacteria*
- 714 #4 MeSH descriptor: [beta-Lactams] explode all trees and with qualifier(s): [administration &
- 715 dosage - AD,
- 716 therapeutic use - TU]
- 717 #5 MeSH descriptor: [Chloramphenicol] explode all trees and with qualifier(s): [administration & 718 dosage - AD, therapeutic use - TU]
- 719 #6 MeSH descriptor: [Aminoglycosides] explode all trees and with gualifier(s): [administration & 720 dosage - AD, therapeutic use - TU]
- 721 #7 MeSH descriptor: [Glycopeptides] explode all trees and with gualifier(s): [administration &
- 722 dosage - AD, therapeutic use - TU]
- 723 #8 MeSH descriptor: [Rifamycins] explode all trees and with qualifier(s): [administration & dosage 724 - AD, therapeutic use - TU]
- 725 #9 MeSH descriptor: [Streptogramins] explode all trees and with gualifier(s): [administration &
- 726 dosage - AD, therapeutic use - TU]

- 727 #10 MeSH descriptor: [Sulfonamides] explode all trees and with gualifier(s): [administration & $7\overline{28}$ dosage - AD, therapeutic use - TU] 729 #11 MeSH descriptor: [Macrolides] explode all trees and with qualifier(s): [administration & 730 dosage - AD, therapeutic use - TU] 731 #12 MeSH descriptor: [Tetracyclines] explode all trees and with gualifier(s): [administration & 732 dosage - AD, therapeutic use - TU] 733 #13 MeSH descriptor: [Oxazolidinones] explode all trees and with qualifier(s): [administration & 734 dosage - AD, therapeutic use - TU] 735 #14 MeSH descriptor: [Quinolones] explode all trees and with qualifier(s): [administration & 736 dosage - AD, therapeutic use - TU] 737 #15 MeSH descriptor: [Lipopeptides] explode all trees and with qualifier(s): [administration & 738 dosage - AD, therapeutic use - TUI 739 #16 MeSH descriptor: [Anti-Bacterial Agents] this term only and with gualifier(s): [administration & dosage - AD, therapeutic use - TUI 740 741 #17 (antibiotic*):ti,ab,kw 742 #18 MeSH descriptor: [Drug Therapy, Combination] this term only 743 #19 MeSH descriptor: [Drug Combinations] this term only 744 #20 MeSH descriptor: [Trimethoprim, Sulfamethoxazole Drug Combination] this term only 745 #21 MeSH descriptor: [Drug Synergism] this term only 746 #22 ((combination):ti,kw,ab) NEAR/3 ((therapy):ti,kw,ab OR (therapies):ti,ab,kw) 747 #23 (combinationtherap*):ti,ab,kw 748 #24 MeSH descriptor: [Drug Resistance, Bacterial] explode all trees 749 #25 MeSH descriptor: [Drug Resistance, Microbial] this term only 750 #26 (resistan*):ti.ab.kw 751 #27 MeSH descriptor: [Complementary Therapies] explode all trees 752 #28 MeSH descriptor: [Plant Extracts] explode all trees 753 #29 (bismuth):ti.ab.kw 754 #30 MeSH descriptor: [Bismuth] explode all trees 755 #31 {OR # 1-# 3} 756 #32 {OR # 4-#17} 757 #33 {OR #18-#23} 758 #34 {OR #24-#26} 759 #35 {AND #31-#34} 760 #36 {OR # 27-#30} 761 #37 #35 NOT #36 762 11.3. EMBASE 763 #26. #24 AND #25 764 #25. 'controlled clinical trial'/exp 765 #24. #23 NOT #22 766 #23. #18 AND #19 AND #20 AND #21 767 #22. #14 OR #15 OR #16 OR #17 768 #21. #12 OR #13 769 #20. #7 OR #8 OR #9 OR #10 OR #11 770 #19. #5 OR #6 771 #18. #1 OR #2 OR #3 OR #4 772 #17. 'herbal medicine'/exp 773 #16. 'alternative medicine'/exp 774 #15. 'bismuth'/exp 775 #14. bismuth:ti,ab,kw 776 #13. resistan*:ti,ab,kw 777 #12. 'antibiotic sensitivity'/exp 778 #11. (combination NEAR/3 (therapy OR therapies)):ti,ab,kw 779 #10. combinationtherap*:ti.ab.kw 780 #9. 'antibiotic agent'/exp/dd cb 781 #8. 'drug potentiation'/de
- 782 #7. 'combination drug therapy'/de

- 783 #6. 'antibiotic*':ti,ab,kw
- 784 #5. 'antibiotic agent'/exp
- 785 #4. (infection:ti,ab,kw OR infections:ti,ab,kw) AND bacteria*
- 786 #3. 'bacterial infection'/exp
- 787 #2. 'bacterium'/exp
- 788 #1. 'prokaryotes by outer appearance'/exp789

790 **11.4.** Screening of eligible trials and previous meta-analyses791

In addition to the systematic database search, we also screened the references of eligible studies and the trials included in two previous meta-analyses (72, 75). With the database search we identified 41 studies. While screening the references of those 41 studies we identified one additional study (45), which meets our inclusion criteria. This additional study was not identified in our search strategy as neither the abstract nor database specific identifiers gave any indication that resistance was measured in this study. The screening of the trials included in two previous analyses did not result in inclusion of further studies (table S12).

800 SI References

Kerantzas Christopher A, Jacobs William R, Rubin Eric J, Collier RJ. Origins of
 Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development
 and Application. mBio.8(2):e01586-16.

Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis
undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with
relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-79.

807 3. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB
808 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:14898.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et
al. Colistin alone versus colistin plus meropenem for treatment of severe infections
caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised
controlled trial. The Lancet Infectious Diseases. 2018;18(4):391-400.

813 5. Kaye Keith S, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C-H, Daikos G, et
814 al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant
815 Organisms. NEJM Evidence. 2022;2(1):EVIDoa2200131.

816 6. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al.
817 Role of vancomycin as a component of oral nonabsorbable antibiotics for microbial
818 suppression in leukemic patients. Antimicrobial agents and chemotherapy.
819 1979;15(3):455-60.

820 7. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of
821 experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim,
822 trimethoprim-sulfamethoxazole, or placebo. Reviews of infectious diseases.
823 1982;4(2):540-5.

8. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al.
Clarithromycin and ethambutol with or without clofazimine for the treatment of
bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS
(london, england). 1997;11(3):311-7.

828 9. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al.
829 Prospective randomized comparison of imipenem monotherapy with imipenem plus
830 netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial
831 agents and chemotherapy. 1994;38(6):1309-13.

10. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and
pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, openlabel, partly randomised trial in patients with drug-susceptible or drug-resistant
pulmonary tuberculosis. Lancet (london, england). 2015;385(9979):1738-47.

Barton 11. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute
leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and
colistin. Annals of internal medicine. 1987;106(1):7-11.

B40 12. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar
Y, et al. Colistin Resistance Development Following Colistin-Meropenem Combination
Therapy vs. Colistin Monotherapy in Patients with Infections Caused by CarbapenemResistant Organisms. Clinical infectious diseases : an official publication of the

844 Infectious Diseases Society of America. 2019.

Bubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A
randomized evaluation of ethambutol for prevention of relapse and drug resistance during

treatment of Mycobacterium avium complex bacteremia with clarithromycin-based
combination therapy. Journal of Infectious Diseases. 1997;176(5):1225-32.

B49 14. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino
P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious
infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter,
randomized clinical trial. Clinical infectious diseases. 2013;57(3):349-58.

Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M.
Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for
Mycobacterium avium complex septicemia in AIDS patients. European journal of clinical
microbiology & infectious diseases. 1999;18(1):16-22.

B57 16. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE,
et al. Prospective randomized comparison of mezlocillin therapy alone with combined
ampicillin and gentamicin therapy for patients with cholangitis. Archives of internal
medicine. 1989;149(6):1279-84.

17. Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised
trial of empirical antibiotic therapy in febrile neutropenic patients with hematological
disorders: ceftazidime versus azlocillin plus amikacin. Australian and new zealand
journal of medicine. 1989;19(5):417-25.

18. Haase DA, Harding GK, Thomson MJ, Kennedy JK, Urias BA, Ronald AR.
Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of
women with localized, acute, symptomatic urinary tract infections and antimicrobial
effect on periurethral and fecal microflora. Antimicrobial agents and chemotherapy.
1984;26(4):481-4.

Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, et al.
Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus
rifampicin versus linezolid for the treatment of MRSA infection. Journal of antimicrobial
chemotherapy. 2015;70(1):264-72.

874 20. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin
875 compared with conventional intravenous treatment for Pseudomonas aeruginosa infection
876 in adults with cystic fibrosis. Lancet (london, england). 1987;1(8527):235-7.

877 21. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of
878 ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin
879 for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora.
880 Chemotherapy. 1988;34 Suppl 1:21-9.

Hultén K, Jaup B, Stenquist B, Engstrand L. Combination treatment with
ranitidine is highly efficient against Helicobacter pylori despite negative impact of
macrolide resistance. Helicobacter. 1997;2(4):188-93.

Iravani A, Richard GA, Baer H, Fennell R. Comparative efficacy and safety of
 nalidixic acid versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract

886 infections in college-age women. Antimicrobial agents and chemotherapy.

887 1981;19(4):598-604.

888 24. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL.

889 Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.

890 Infection. 1993;21(4):223-8.

891 Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. 25. 892 Alterations of human skin microbiome and expansion of antimicrobial resistance after 893 systemic antibiotics. Sci Transl Med. 2021;13(625):eabd8077. 894 26. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination. 895 Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. 896 South African medical journal. 1994;84(6):325-8. 897 27. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole 898 compared with vancomycin for the treatment of Staphylococcus aureus infection. Annals 899 of internal medicine. 1992;117(5):390-8. 900 Mavromanolakis E, Maraki S, Samonis G, Tselentis Y, Cranidis A. Effect of 28. 901 norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women 902 with recurrent urinary tract infections. Journal of chemotherapy (florence, italy). 903 1997;9(3):203-7. 904 29. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. 905 Comparison of combination therapy regimens for treatment of human immunodeficiency 906 virus-infected patients with disseminated bacteremia due to Mycobacterium avium. 907 ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clinical 908 infectious diseases. 1997:25(3):621-9. 909 30. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. 910 Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of 911 respiratory infections in children with cystic fibrosis. Pediatric pulmonology. 912 1988:4(4):201-4. 913 31. Menon R, Roberts FE, Barr KW, Howard H, Lord VL, Hegarty MA, et al. 914 Comparison of a slow-release trimethoprim with co-trimoxazole: efficacy and selection 915 of resistance in the Enterobacteriaceae. Journal of antimicrobial chemotherapy. 916 1986;18(3):415-20. 917 Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, et al. 32. 918 Comparison of omeprazole, metronidazole and clarithromycin with 919 omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. 920 Digestion. 1998;59(6):646-50. 921 33. Parras F, Guerrero MC, Bouza E, Blázquez MJ, Moreno S, Menarguez MC, et al. 922 Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in 923 eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. 924 Antimicrobial agents and chemotherapy. 1995;39(1):175-9. 925 Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of 34. 926 pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin 927 and gentamicin. J Pediatr. 1977:90(1):144-8. 928 35. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. 929 Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-930 azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant 931 typhoid fever. Antimicrobial agents and chemotherapy. 2007;51(3):819-25. 932 Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, et al. 36. 933 Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by 934 meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ (clinical 935 research ed). 2015;350:h2219.

936 Pogue JM, Rybak MJ, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, et al. 37. 937 Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination 938 Therapy with Meropenem. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S418-S9. 939 Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. 38. 940 Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant 941 Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin 942 Infect Dis. 2021;72(9):1517-25. 943 Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al. Ceftazidime 39. 944 monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative 945 infections. Clinical Infectious Diseases. 1995;20(5):1217-28. 946 40. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim-947 sulfamethoxazole in the treatment of urinary tract infections. Journal of urology. 948 1981:125(6):825-7. 949 41. Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection 950 biological effects on vaginal and fecal flora. Journal of urology. 1985;133(4):628-30. 951 Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. 42. 952 Comparison of a β -lactam alone versus β -lactam and an aminoglycoside for pulmonary 953 exacerbation in cystic fibrosis. Journal of Pediatrics. 1999;134(4):413-21. 954 Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, et al. 43. 955 Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the 956 eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic 957 ulceration. American journal of gastroenterology. 1998;93(10):1909-13. 958 Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. 44. 959 Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-960 sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: 961 prevention of antimicrobial resistance and effect of host factors on outcome. 962 Antimicrobial agents and chemotherapy. 1993;37(6):1334-42. 963 Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus 45. 964 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J 965 Med. 1986;80(5):884-90. 966 Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus 46. 967 vancomycin/polymyxin for prevention of infections in granulocytopenic patients. 968 American journal of medicine. 1990;88(1):36-42. 969 47. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. 970 Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-971 10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. 972 Alimentary pharmacology & therapeutics. 1997;11(5):943-52. 973 Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven 48. 974 random-effects models for meta-analyses that estimate the summary odds ratio. Stat Med. 975 2018;37(7):1059-85. 976 49. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. 977 Journal of Statistical Software. 2010;36(3):1 - 48. 978 Günhan BK, Röver C, Friede T. Random-effects meta-analysis of few studies 50. 979 involving rare events. Research Synthesis Methods. 2020;11(1):74-90. 980 Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in 51.

982 52. Mitchison DA, Selkon JB. Bacteriological aspects of a survey of the incidence of 983 drug-resistant tubercle bacilli among untreated patients. Tubercle. 1957;38(2):85-98. 984 Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of 53. 985 drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A 986 national survey, 1955-56. Tubercle. 1957;38(2):71-84. 987 54. Handel A, Margolis E, Levin BR. Exploring the role of the immune response in 988 preventing antibiotic resistance. J Theor Biol. 2009;256(4):655-62. 989 Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, 55. 990 Hartemann P, et al. Antibiotic resistance: What is so special about multidrug-resistant 991 Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05. 992 56. Cacace E, Kim V, Varik V, Knopp M, Tietgen M, Brauer-Nikonow A, et al. 993 Systematic analysis of drug combinations against Gram-positive bacteria. Nature 994 Microbiology. 2023;8(11):2196-212. 995 Vrancianu CO, Popa LI, Bleotu C, Chifiriuc MC. Targeting Plasmids to Limit 57. 996 Acquisition and Transmission of Antimicrobial Resistance. Frontiers in Microbiology. 997 2020;11. 998 58. Goessweiner-Mohr N, Arends K, Keller W, Grohmann E, Tolmasky Marcelo E, 999 Alonso Juan C. Conjugation in Gram-Positive Bacteria. Microbiology Spectrum. 1000 2014;2(4):2.4.19. 1001 59. Cazares A, Moore MP, Hall JPJ, Wright LL, Grimes M, Emond-Rhéault J-G, et 1002 al. A megaplasmid family driving dissemination of multidrug resistance in Pseudomonas. 1003 Nature Communications. 2020;11(1):1370. 1004 Holt KE, Phan MD, Baker S, Duy PT, Nga TVT, Nair S, et al. Emergence of a 60. 1005 Globally Dominant IncHI1 Plasmid Type Associated with Multiple Drug Resistant 1006 Typhoid. PLOS Neglected Tropical Diseases. 2011;5(7):e1245. 1007 61. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. 1008 Clin Microbiol Rev. 2005;18(4):657-86. 1009 62. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 1010 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 1011 2018;46(D1):D1074-d82. 1012 63. Ursu O, Holmes J, Bologa CG, Yang JJ, Mathias SL, Stathias V, et al. 1013 DrugCentral 2018: an update. Nucleic Acids Research. 2019;47(D1):D963-D70. 1014 64. McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr. 1015 2020;43(2):45-8. 1016 65. Bartoń K. MuMIn: Multi-Model Inference. 2020. 1017 66. Burnham KP, Anderson DR. Model selection and multimodel inference : a 1018 practical information-theoretic approach. Second edition. ed. New York, New York: 1019 Springer; 2002. 1020 67. Symonds MRE, Moussalli A. A brief guide to model selection, multimodel 1021 inference and model averaging in behavioural ecology using Akaike's information 1022 criterion. Behavioral Ecology and Sociobiology. 2011;65(1):13-21. 1023 68. Anderson DR. Model Based Inference in the Life Sciences : A Primer on 1024 Evidence. 1st ed. 2008. ed. New York, NY: Springer New York; 2008. 1025 Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain 69. 1026 Med (Seoul). 2021;16(2):138-50.

1027 70. Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic 1028 reviews with meta-analysis. BMC medical research methodology. 2017;17(1):1-18. 1029 71. Tamma Pranita D, Cosgrove Sara E, Maragakis Lisa L. Combination Therapy for 1030 Treatment of Infections with Gram-Negative Bacteria. Clinical Microbiology Reviews. 1031 2012;25(3):450-70. 1032 Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic 72. monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for 1033 1034 sepsis. Cochrane Database of Systematic Reviews. 2014(1). 1035 Ye C, Wang C, Li Z, Li X, Pan J, Liu L, et al. The Effect of Combination Therapy 73. 1036 on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A 1037 Systematic Review and Meta-analysis of Randomized Controlled Trials. Infectious 1038 Diseases and Therapy. 2021;10(4):2643-60. 1039 Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. 74. 1040 Monotherapy versus combination therapy for multidrug-resistant Gram-negative 1041 infections: Systematic Review and Meta-Analysis. Scientific Reports. 2019;9(1):15290. 1042 Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect 75. 1043 of Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy 1044 on the Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, 1045 Controlled Trials. Clinical Infectious Diseases. 2005;41(2):149-58. 1046 Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, et al. 76. 1047 Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter 1048 pylori by factorial design in a randomized, double-blind, controlled study. Aliment 1049 Pharmacol Ther. 1998;12(5):439-45. 1050 77. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, et al. 1051 Clarithromycin or rifabutin alone or in combination for primary prophylaxis of 1052 Mycobacterium avium complex disease in patients with AIDS: A randomized, double-1053 blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn 1054 Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 1055 2000;181(4):1289-97. 1056 78. Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, et al. 1057 Eradication of Helicobacter pylori by 7-Day Triple-Therapy Regimens Combining 1058 Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic 1059 Ulcer Disease: Results of Two Double-Blind, Randomized Studies. Helicobacter. 1060 2003;8(6):626-42. 1061 79. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin 1062 for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988;7(3):171-1063 6. 1064 Bow EJ, Rayner E, Scott BA, Louie TJ. Selective gut decontamination with 80. 1065 nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic 1066 cancer patients: relationship of efficacy to antimicrobial spectrum and timing of 1067 administration. Antimicrob Agents Chemother. 1987;31(4):551-7. 1068 Cruciani M, Concia E, Navarra A, Perversi L, Bonetti F, Aricò M, et al. 81. 1069 Prophylactic co-trimoxazole versus norfloxacin in neutropenic children — perspective 1070 randomized study. Infection. 1989;17(2):65-9. 1071 Dalgic N, Karadag CA, Bayraktar B, Sancar M, Kara O, Pelit S, et al. Ertapenem 82. 1072 versus standard triple antibiotic therapy for the treatment of perforated appendicitis in

1073 pediatric patients: a prospective randomized trial. Zeitschrift fur Kinderchirurgie [Surgery 1074 in infancy and childhood]. 2014;24(5):410-8. 1075 de Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, et al. A 83. 1076 randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the 1077 empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents 1078 Chemother. 1985;28(6):824-8. 1079 de Pauw BE. [Results of several different controlled studies with ceftazidime in 84. 1080 the treatment of infections in immunosuppressed patients]. Infection. 1987;15 Suppl 1081 4:S168-72. 1082 85. Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, et al. 1083 Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of 1084 intra-abdominal infections: observations from two randomized comparative clinical trials 1085 of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005;24(7):443-9. 1086 86. CONTROLLED CLINICAL TRIAL OF SHORT-COURSE (6-MONTH) 1087 REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY 1088 TUBERCULOSIS: EAST AFRICAN/BRITISH MEDICAL RESEARCH COUNCILS. 1089 The Lancet. 1972;299(7760):1079-85. 1090 Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A 87. 1091 multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus 1092 ceftriaxone in hospitalized adults with moderate to severe community-acquired 1093 pneumonia. Clin Ther. 2002;24(8):1292-308. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of 1094 88. 1095 ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory 1096 exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985;4(2):172-7. 1097 Grossman RF, Beaupre A, LaForge J, Lampron N, Hanna K. A prospective 89. 1098 randomised parallel single-blind comparison of oral ciprofloxacin with oral 1099 cotrimoxazole in the treatment of respiratory tract infections in patients with chronic 1100 obstructive lung disease. Drug Investigation. 1994;8(2):110-7. 1101 90. Grabe M, Forsgren A, Hellsten S. The effectiveness of a short perioperative 1102 course with piyampicillin/piymecillinam in transurethral prostatic resection: clinical 1103 results. Scand J Infect Dis. 1986;18(6):567-73. 1104 Guerrant RL, Wood SJ, Krongaard L, Reid RA, Hodge RH. Resistance among 91. 1105 fecal flora of patients taking sulfamethoxazole-trimethoprim or trimethoprim alone. 1106 Antimicrob Agents Chemother. 1981;19(1):33-8. 1107 92. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of 1108 combination versus monotherapy for the empiric treatment of suspected ventilator-1109 associated pneumonia. Crit Care Med. 2008;36(3):737-44. 1110 93. Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD. 1111 Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute 1112 pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis. 1986;5(4):440-3. 1113 94. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, et al. Ofloxacin 1114 versus co-trimoxazole for prevention of infection in neutropenic patients following 1115 cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34(2):215-8. 1116 McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Goldmann DA. 95. 1117 Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary 1118 exacerbations of cystic fibrosis. J Antimicrob Chemother. 1983;11 Suppl B:195-203.

1119 96. Muder RR, Boldin M, Brennen C, Hsieh M, Vickers RM, Mitchum K, et al. A 1120 controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for 1121 eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J 1122 Antimicrob Chemother. 1994;34(1):189-90. 1123 Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, et 97. 1124 al. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary 1125 infections in cystic fibrosis. Pediatr Infect Dis J. 1987;6(7):648-53. 1126 Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as 98. 1127 antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J. 1128 1997;16(1):106-11; discussion 23-6. 99. 1129 Shawky D, Salamah AM, Abd-Elsalam SM, Habba E, Elnaggar MH, Elsawy AA, 1130 et al. Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter 1131 pylori infection in children and adolescents: a randomized trial. Eur Rev Med Pharmacol 1132 Sci. 2022;26(9):3132-7. 1133 Sun Y, Fan J, Chen G, Chen X, Du X, Wang Y, et al. A phase III, multicenter, 100. 1134 double-blind, randomized clinical trial to evaluate the efficacy and safety of 1135 ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants 1136 with complicated intra-abdominal infections. International Journal of Infectious Diseases. 1137 2022;123:157-65. 1138 101. Carbon C, Auboyer C, Becq-Giraudon B, Bertrand P, Gallais H, Mouton Y, et al. 1139 Cefotaxime (C) vs cefotaxime + amikacin (C + A) in the treatment of septicemia due to 1140 enterobacteria: a multicenter study. Chemioterapia. 1987;6(2 Suppl):367-8. Cone LA, Woodard DR, Stoltzman DS, Byrd RG. Ceftazidime versus 1141 102. 1142 tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob Agents 1143 Chemother. 1985;28(1):33-6. 1144 Croce MA, Fabian TC, Stewart RM, Pritchard FE, Minard G, Trenthem L, et al. 103. 1145 Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma 1146 patients. J Trauma. 1993;35(2):303-9; discussion 9-11. 1147 Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al. 104. 1148 Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-1149 aminoglycoside combination regimens in the empirical treatment of serious bacterial 1150 infections. Antimicrob Agents Chemother. 1983;24(3):388-93. 1151 105. Iakovlev SV, Iakovlev VP, Derevianko, II, Kira EF. [Multicenter open 1152 randomized trial of meropenem in comparison to ceftazidime and amikacin used in 1153 combination in severe hospital infections]. Antibiot Khimioter. 1998;43(1):15-23. 1154 106. Klastersky J, Cappel R, Daneau D. Therapy with carbenicillin and gentamicin for 1155 patients with cancer and severe infections caused by gram-negative rods. Cancer. 1156 1973;31(2):331-6. 1157 107. Mandell LA, Nicolle LE, Ronald AR, Landis SJ, Duperval R, Harding GK, et al. 1158 A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the 1159 treatment of hospitalized patients with pneumonia. J Antimicrob Chemother. 1987;20(1):95-107. 1160 1161 108. Sculier JP, Coppens L, Klastersky J. Effectiveness of mezlocillin and 1162 endotracheally administered sisomicin with or without parenteral sisomicin in the 1163 treatment of Gram-negative bronchopneumonia. J Antimicrob Chemother. 1982;9(1):63-1164 8.

- 1165 109. Randomized multicenter clinical trial with imipenem/cilastatin versus
- 1166 cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections.
- 1167 German and Austrian Imipenem/Cilastatin Study Group. Eur J Clin Microbiol Infect Dis.
- 1168 1992;11(8):683-92.